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CHAPTER 1 
 
 
INTRODUCTION 
 
 
 
1.1 Copper: an essential yet potentially toxic nutrient 
 
 
 
Copper (Cu) is an essential micronutrient and contributes to various enzymatic 
processes involved in health, development and disease conditions. As a 
transition metal, Cu can exist in two oxidation states, Cu1+ or Cu2+ and thus 
serves as an important structural component and as a cofactor to numerous 
enzymes that catalyze oxygen utilization, electron transfer, and hydrolytic 
reactions. These copper-dependent enzymes include cytochrome c oxidase 
(CCO), the last enzyme involved in electron transfer and oxygen utilization at 
complex IV of the mitochondrial respiratory chain; copper/zinc superoxide 
dismutase (Cu/Zn SOD), involved in antioxidant defense; lysyl oxidase, essential 
for the cross-linking of elastin and collagen fibrils in connective tissue; dopamine 
β hydroxylase; required for the synthesis of catecholamines; and tyrosinase 
enzyme, involved in pigmentation (1). Imbalances in mammalian Cu homeostasis 
can lead to defects in connective tissue formation, loss of pigmentation, 
neurological disorders, toxicity and others. Excess Cu causes toxicity due, in 
part, to the ability of Cu to non-specifically displace other metal ions from 
enzymes, leading to loss of enzyme activity (2). Excess Cu is also toxic due to its 
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ability to generate reactive oxygen species (ROS). The redox activity of the Cu 
ion, although essential for its function as a cofactor for several enzymes, also 
allows it to participate in the Fenton reaction and to generate the highly 
damaging hydroxyl radical (OH•), thus increasing the need for a tight regulation 
of copper homeostasis (2).  
 
 
1.2 Dietary copper sources 
 
 
 
The dietary reference intakes of Cu in adults are between 0.7 mg/day and 1.3 
mg/day with potential toxic intakes levels set at doses exceeding 5 mg/day. The 
total body Cu content for an adult human varies between 70 mg-100 mg (3-6).  
The highest concentration of Cu in organs of healthy adult individuals is in the 
liver, kidneys, brain, heart, and gastrointestinal tract, with the lowest 
concentrations in the spleen and lungs (3-6). Most of the daily requirements for 
copper in humans and animals are met by dietary intake. Foods rich in copper 
include organ meat, especially liver and kidneys, shellfish, nuts, grains and 
chocolate. Drinking water contaminated by copper pipes is also a significant 
source of dietary copper (3-6).  
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1.3 Copper deficiency. 
 
 
 
1.3.1 Acquired copper deficiency. 
 
 
 
Copper deficiency has two possible etiologies, acquired or genetic. In humans, 
acquired copper deficiency is a known cause of sideroblastic anemia, and has 
been increasingly associated with neurological degeneration (7-14). Acquired 
copper deficiency in humans is rare, owing to copper’s ubiquitous distribution and 
low daily requirements (15). Known causes of acquired copper deficiency include 
excess zinc ingestion, use of copper chelators, malabsorption, nephritic 
syndrome, copper-deficient parenteral nutrition and enteral feeding, and 
gastrectomy (15, 16). Copper deficiency may also occur in premature and 
malnourished infants (15, 16).  
 
The anemia associated with copper deficiency can be attributed to impaired iron 
absorption, reduced iron transfer from the reticuloendothelial system to the 
circulation and decreased cytochrome c oxidase activity in the mitochondria (17). 
Iron homeostasis is severely affected by copper deficiency, mainly owing to the 
important role of the copper-dependent ferroxidases hephaestin and 
ceruloplasmin in iron uptake and tissue distribution. Hephaestin, which is 
expressed in the duodenal mucosa, oxidizes ferrous iron to the ferric form, thus 
facilitating its transfer across the basolateral membrane for loading onto apo-
transferrin in the blood (17, 18). On the other hand, oxidation of iron by 
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ceruloplasmin facilitates its transfer from reticuloendothelial cells to apo-
transferrin in the circulation (17, 18). The anemia associated with copper 
deficiency is associated with the formation of ring sideroblasts owing to the 
accumulation of iron in the mitochondria (19). This is due to the suppressed 
activity of cytochrome c oxidase, resulting in insufficient generation of reducing 
equivalents necessary to reduce mitochondrial iron from the ferric to ferrous state 
(20, 21). Since only ferrous iron can by used by ferrochelatase for heme 
synthesis (22, 23), the defect in cytochrome c oxidase activity ultimately results in 
intramitochondrial iron accumulation and consequently in increased production of 
reactive oxygen species (ROS) and damage to the mitochondrial DNA (24, 25). 
The hematological manifestations caused by copper deficiency are quickly 
reversed by copper supplementation (16, 26, 27). 
 
Copper is an important cofactor in several enzymatic processes important for the 
function of the central nervous system. These include cytochrome c oxidase, 
copper-zinc superoxide dismutase (SOD1), and dopamine ß-hydroxylase (1). 
The association of neurological symptoms with copper deficiency has been 
increasingly recognized over the past decade (9, 10, 13, 14, 27, 28). The most 
common neurological symptom is ataxic myelopathy with or without neuropathy 
(7, 9-14, 16, 27-30). This clinical picture is similar to the progressive ataxic 
myelopathy or “swayback” in ruminant animals fed copper-deficient diets. Other 
neurological disorders associated with copper deficiency are central nervous 
system demyelination (13), peripheral neuropathy (31), and optic neuropathy 
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(31). Acute optic myeloneuropathy is a recognized adverse side effect of the 
copper-zinc chelator clioquinol (32). Correction of the hypocupremia in acquired 
copper deficiency usually arrests the neurological deterioration and may result in 
clinical improvement (11, 16, 26, 27).  
 
 
1.3.2 Genetic copper deficiency – Menkes disease. 
 
 
 
Despite the recent recognition of the neurological manifestations of acquired 
copper deficiency, there exists a well-documented precedent in the clinical 
syndrome Menkes disease. Menkes disease is an X-linked inherited disorder of 
copper malabsorption which develops in infancy and results in various 
neurological and systemic symptoms (33-42). In 1972, David Danks made the 
critical connection between the kinky/steely hair in Menkes patients and that of 
lambs grazing on grass grown in copper-depleted soil (38, 39). His research 
provided the first evidence that Menkes patients had abnormally low serum 
copper levels, while biopsies from patients’ guts revealed unusually high levels of 
accumulated copper, establishing the fact that a defect in copper transport was 
the underlying cause of Menkes disease. This work finally led to the identification 
and cloning of the Menkes gene (43).  
 
The Menkes gene codes for the Cu transporting P-type ATPase, ATP7A, also 
known as MNK protein (43-45). ATP7A is ubiquitously expressed in the human 
body except in the liver, where the related ATP7B or Wilson protein is expressed 
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(discussed later). ATP7A is essential for the intestinal uptake of copper and its 
delivery to the circulation (Fig. 1.1). Menkes disease is characterized by reduced 
transport of dietary copper across the basolateral membrane of intestinal 
enterocytes to the hepatic portal circulation, resulting in the hyperaccumulation of 
copper within the intestinal mucosa and the deficiency of copper in the circulation 
and peripheral organs (38). This copper deficiency is further exacerbated by 
reduced copper transport into the central nervous system across the blood brain 
barrier (38). Furthermore, copper transport across fetally derived placental cells 
is also impaired, resulting in defective transport of copper from the mother to the 
Menkes fetus during gestation (46, 47). The incidence of Menkes disease has 
been reported to vary between 1:50,000 to 1:100,000 (36). The copper deficiency 
symptoms associated with Menkes disease are exhibited starting the second or 
third month of life. These symptoms include skin laxity, hypopigmentation, 
kinky/steely hair, neurological impairment and convulsions (46). Autopsies of 
Menkes patients have revealed demyelination in spinal cord white matter, 
reminiscent of that observed in copper-deficient ruminants suffering from 
“swayback” (48). The copper-dependent enzyme lysyl oxidase is important in the 
cross-linking of collagen and elastin (49), and its deficient activity in Menkes 
disease results in vascular and microvascular system abnormalities (50). These 
include tortuous blood vessels, particularly affecting the blood flow in the brain 
(51).  
 
Another significant defect of Menkes disease is immune system dysregulation. 
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Menkes patients are prone to infections, particularly of the lungs and urinary tract 
(52-55). Copper is critical for the function of the immune system (discussed later) 
(56) however, it is unknown whether the immune deficiencies in Menkes patients 
may be attributed to a direct role for ATP7A in immune defense. Most Menkes 
patients die during early childhood, however mild allelic forms of the disease 
exist, such as occipital horn syndrome (57) and mild Menkes disease, which are 
caused by a similar abnormality in copper metabolism but differ in clinical 
presentation and survival potential (34, 58-63). OHS is characterized by 
prominent protuberance of the occipital bone, which is absent in classical 
Menkes disease. Other OHS symptoms include skeletal abnormalities and 
connective tissue abnormalities, including skin laxity and blood vessel tortuosity 
(62, 63). OHS patients exhibit borderline average intelligence and often survive 
until adulthood. Mild Menkes disease patients typically lack the connective tissue 
defects of classical Menkes disease and present with neuro-developmental 
delays and mild ataxia (34, 58-61).  
 
Despite studies identifying the mutations affecting the Menkes gene in each 
variation of the disease, the biochemical basis for this clinical diversity is still 
unknown. The current accepted treatment for Menkes disease is parenteral 
administration of copper (i.e. intravenous copper injections). When initiated in 
newborn Menkes disease babies, parenteral copper nutrition can prevent 
neurological degeneration in some, but not all, cases. Unfortunately, if treatment 
is started in babies with classical Menkes disease above the age of 2 months, it 
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does not improve the neurological degeneration. Moreover, early copper 
parenteral administration does not improve the non-neurological defects such as 
connective tissue laxity. Further studies are needed to develop alternative 
therapies for Menkes disease and occipital horn syndrome (64-66). 
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FIGURE 1.1 The ATP7A protein is critical for the entry and distribution of 
dietary copper. Copper transport across the basolateral membrane of 
enterocytes occurs via the ATP7A protein. ATP7A is required to transport copper 
across the blood-brain barrier, and across the placenta. The locations of copper 
transport pathways mediated by ATP7A are based on sites of copper 
accumulation in patients with Menkes disease, and animal models. Copper is 
secreted from the liver in the bile via the Wilson disease protein (not shown). 
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Fig. 1.1 
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1.4 Copper toxicity 
 
 
 
As with copper deficiency, copper toxicity can be either acquired or genetic. 
Acquired copper toxicity may be caused by excessive copper supplementation, 
food contamination, and low dietary zinc levels (67, 68). Long-term exposure to 
high levels of copper causes tissue damage and liver cirrhosis due to excess 
tissue copper accumulation. This is also true for Wilson disease, an autosomal 
recessive disorder of copper metabolism which results in hepatic damage 
presenting as progressive hepatic cirrhosis and rapidly progressive liver failure 
and liver fibrosis (69). Patients suffering from Wilson disease carry mutations in 
the gene encoding the Cu-ATPase ATP7B, or Wilson protein (69, 70). ATP7B is 
highly homologous to ATP7A, sharing 57% sequence identity, and is mainly 
expressed in the liver and brain (71). In the liver, ATP7B functions in delivering 
copper to the secretory pathway and also in copper export into the bile. ATP7B-
dependent copper export into the bile and subsequently through the bowel is the 
major route of copper excretion from the body. Wilson disease greatly impairs 
copper transport to the secretory pathway and copper release into the bile, 
resulting in marked accumulation of copper in the liver, low serum levels of 
copper-bound ceruloplasmin and low biliary copper content (72-74). ATP7B 
inactivity is also associated with copper accumulation in the brain, resulting in 
severe neurological abnormalities such as movement disorders and psychiatric 
manifestations (69, 75, 76). The neurological disorders in Wilson disease 
patients are often accompanied with accumulation of copper deposits in the 
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cornea resulting in the Kayser-Fleischer corneal pigment ring, which is a 
characteristic and diagnostic sign of the disease (77, 78). This is likely due to the 
lack of ATP7B, which is normally expressed in the retinal pigment epithelium and 
the ciliary body during retinal development (77, 78). 
 
The treatment of copper toxicosis in Wilson disease involves copper chelation 
therapy using D-penicillamine, which binds copper and facilitates its secretion in 
urine (79). However, D-penicillamine administration is not always successful and 
may have severe side effects (80-82), which has prompted the development of 
alternative therapeutic treatments, such as chelation with trientine, 
tetrathiomolybdate (TTM) or the administration of zinc salts (83-85). Further 
evaluation of the efficacy and potential side effects of these alternative therapies 
remains to be performed.   
 
 
 1.5 Intestinal copper absorption 
 
 
 
Absorption of dietary copper in mammals occurs exclusively through the 
digestive tract. Occasionally, copper may enter the body through the skin if 
applied in high concentrations in the form of ointment or if copper bracelets are 
worn (4, 68, 86). Copper absorption occurs primarily in the small intestine 
through a highly efficient mechanism. At moderate dietary intakes, 55-75% of 
copper is absorbed in adults, and this percentage does not drop significantly with 
advanced age (4, 68, 87). Interestingly, intestinal copper reabsorption from saliva 
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(0.33-0.45 mg/d), gastric juices (1 mg/d), pancreatic fluids (0.4-1.3 mg/d) and 
duodenal fluids (0.4-2.2 mg/d), contributes a total of 4-7.5 mg/d additional Cu to 
the digestive tract, compared to an average of 1 mg/d available from dietary 
sources (4, 68, 87). Copper excretion occurs mainly through the bile and sheds 
an average of 0.5-1.5 mg/d of body copper.  
 
 
1.5.1 Absorption at the apical membrane of intestinal enterocytes. 
 
 
 
The process of copper absorption at the apical side of intestinal epithelial cells is 
the subject of on-going studies. It has been suggested that intestinal Cu 
absorption occurs via a carrier-mediated saturable process (67, 68). 
Furthermore, the efficiency of Cu uptake is regulated by dietary Cu levels, i.e. 
efficiency of absorption increases when dietary Cu content is low (88). This 
suggests the presence of one or more specific molecules responsible for 
intestinal copper absorption, and the possibility that dietary copper levels 
regulate the expression, activity or localization of these molecules. One potential 
candidate is the broad spectrum metal transporter DMT1 (divalent metal 
transporter, also known as Nramp2/DCT1), which shows specificity for divalent 
metal ions such as Fe2+, Mn2+, Zn2+, Co2+, Cd2+ and Cu2+ (89), and studies have 
shown that DMT1 transports Cu1+ into cultured polarized epithelial cells (90, 91). 
However, mammalian cell culture studies strongly support a role for the high-
affinity copper transporter CTR1 in Cu uptake (92-94). CTR1 is expressed in the 
intestines, and is localized to the apical membrane of intestinal enterocytes (94). 
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CTR1 transports Cu with high specificity at a Km of ∼1 µM in an ATP-
independent manner. There is strong accumulating evidence suggesting that 
CTR1 specifically transports Cu1+, because yeast CTR1 requires the cell-surface 
Cu2+/Fe3+ metalloreductases Fre1 and Fre2 for its optimal activity (95). 
Furthermore, the reducing agent ascorbate has been shown to enhance 64Cu 
uptake in yeast and cultured mammalian cells (93). Most copper in food is 
present in the cupric (Cu2+) form, which requires its reduction to the cuprous form 
(Cu1+) prior to its uptake by CTR1 (68). In order to maintain copper in its reduced 
form in the presence of oxygen, it has been suggested that intestinal 
metalloreductases, possibly located in close proximity to CTR1 at the apical 
membrane, serve to reduce the copper and hand it off to CTR1 (96). dCytb is a 
duodenal metalloreductase localized at the apical membrane of intestinal 
enterocytes (97), and has been proposed to facilitate CTR1-mediated Cu1+ 
absorption. It is also possible that an unidentified ligand binds copper following its 
reduction and delivers it to CTR1 (96). Mammalian CTR1 constitutively 
undergoes rapid clathrin-mediated endocytosis at Cu concentrations near the Km 
for transport, leading to the degradation of CTR1 (98, 99). The endocytosis and 
degradation of CTR1 in intestinal epithelial cells may provide a mechanism to 
regulate Cu uptake in response to elevated dietary copper content.  
 
The current model suggests that copper absorption at the intestinal apical 
membrane is primarily mediated by CTR1. A recent study using conditional 
intestinal knockout of CTR1 in mice (CTR1int-/int-) demonstrates a critical role for 
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CTR1 in intestinal copper absorption (100). CTR1int-/int- mice have decreased 
copper accumulation in peripheral organs and deficient activities of Cu-
dependent enzymes, leading to severe hyperaccumulation of liver Fe. The 
knockout mice suffer severe post-natal growth retardation, and usually die 10 to 
21 days postpartum unless rescued with an intraperitoneal (IP) injection of Cu at 
days 5 or 6 after birth. The CTR1int-/int- mice also exhibit symptoms reminiscent of 
those seen in Menkes disease, such as skin laxity, hypopigmentation, and 
vascular defects, as well as cardiac hypertrophy. Surprisingly, intestinal epithelial 
cells from CTR1int-/int- mice reveal an unexpected hyperaccumulation of 
intracellular Cu (7-fold) that is not biologically available, suggesting a critical role 
for CTR1 in copper distribution to intracellular chaperones (100). Decreased 
activities of the Cu-dependent enzymes (such as cytochrome c oxidase), and the 
accumulation of the copper chaperone CCS, which is degraded under elevated 
Cu levels (discussed later), serve as indices for the low bioavailability of Cu in the 
knockout mice enterocytes. These findings suggest an alternative mechanism for 
Cu transport across the apical membrane. It is possible that DMT1 plays the role 
of secondary intestinal copper transporter in the absence of CTR1, however, 
CTR1-mediated transport appears to be critical for the bioavailability of 
intracellular copper pools.  
 
 
1.5.2 Transport across the basolateral membrane of intestinal enterocytes. 
 
 
 
Copper absorption across the basolateral membrane of intestinal epithelial cells 
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occurs via ATP7A. ATP7A is strongly expressed in the duodenum and the upper 
jejunum, suggesting that these are the primary sites of intestinal Cu absorption 
(101). Mutations in the ATP7A gene in Menkes disease result in Cu overload in 
intestinal epithelial cells and copper deficiency in the circulation and peripheral 
organs (discussed earlier) (102, 103). Exposure of intestinal enterocytes to 
dietary copper stimulates the trafficking of ATP7A from its steady-state 
localization in the trans-Golgi network (TGN) to the basolateral membrane, where 
it exports copper into the circulation (101). This provides a regulated mechanism 
of Cu transport from the site of absorption at the apical membrane to the site of 
exit into the hepatic portal circulation (102).  
 
 
1.6 Copper transport and distribution to tissues 
 
 
 
On exiting the GI tract through the basolateral membrane of enterocytes into the 
hepatic portal blood, copper is initially bound to albumin, transcuprein and low 
molecular-weight amino acids such as histidine (68, 104). Albumin and 
transcuprein have been shown to bind Cu with high affinity and copper is readily 
exchanged by these 2 proteins (105). Copper-bound albumin, transcuprein and 
histidine are preferred substrates for the liver (68, 104), where they rapidly 
deliver their bound copper (68, 106, 107). A minor fraction of this copper pool is 
diverted to the kidneys. Copper uptake by the liver and the kidneys is thought to 
be mediated by CTR1 (68, 104). The liver is the major storage site of copper in 
mammals. In the liver, copper is either delivered to copper-dependent enzymes, 
incorporated into metallothionein (MT) and glutathione (108), or, when in excess, 
 17 
released into the bile via ATP7B or Wilson protein (109, 110). This mechanism is 
mediated by copper-dependent trafficking of ATP7B in hepatocytes. ATP7B 
maintains a steady-state localization in the TGN and delivers Cu to the secretory 
compartment to be incorporated into copper-dependent enzymes, including 
ceruloplasmin. In response to elevated Cu levels, ATP7B relocalizes to 
intracellular vesicles near canalicular membranes and pumps excess copper into 
the bile ducts. In the bile, copper is bound to unidentified complexes that render it 
unavailable for intestinal reabsorption (109, 110). ATP7B represents the major 
route of Cu removal in mammals. Genetic ATP7B mutations causing Wilson 
disease are associated with copper toxicosis, due to the inability of ATP7B to 
remove excess Cu from the liver and to incorporate Cu into ceruloplasmin for 
delivery to peripheral tissues.  
 
 
1.6.1 Ceruloplasmin is the major carrier of copper in the circulation. 
 
 
 
Ceruloplasmin-bound Cu is not part of the exchangeable plasma Cu pool, nor 
does ceruloplasmin readily bind or incorporate Cu when exposed to the metal. 
During its synthesis in hepatocytes, 6 copper atoms are incorporated into apo-
ceruloplasmin via copper delivery into the secretory pathway by ATP7B to form 
holo-ceruloplasmin. Although Cp is primarily synthesized in the liver, other cell 
types express the protein, including macrophages, monocytes, astrocytes, and 
Sertoli cells, where ATP7A may function in delivering copper to the enzyme 
(111). Holo-ceruloplasmin (holoCp) is the major carrier of copper in the blood 
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(112-115), and serves to distribute the newly acquired/recycled copper to all 
peripheral organs and tissues. Cp binding has been reported in a range of 
tissues and cells including erythrocytes, aorta and heart, liver endothelium, 
leukocytes, kupffer cells and human placental cells (111). In endothelial cells, Cp 
binding occurs through the galactosyl recognition system (115). Also, a 
glycosylphosphatidylinositol-anchored form of Cp (GPI-linked Cp) has been 
identified in monocytes and astrocytes (116, 117). In addition to its role in copper 
transport, ceruloplasmin also serves to regulate cellular Fe release through its 
ferroxidase activity, and is thought to modulate coagulation, angiogenesis, and 
aid in defense against oxidative stress (111, 118-123).  
 
 
1.6.2 Regulation of ceruloplasmin.  
 
 
 
The concentration of holoCp in the plasma positively correlates with copper 
availability in the liver. However, Cu does not regulate the synthesis or the 
secretion of ceruloplasmin. Physiological conditions that increase the synthesis 
and secretion of ceruloplasmin include the acute-phase inflammatory response 
and relative oxygen depletion or hypoxia (124-132). Cp is an acute-phase 
reactant, and its expression is increased 2- to 3-fold in the plasma during 
infection, suggesting a possible antibacterial role (124-129). It has been 
suggested that Cp may serve as a radical scavenger, however conflicting reports 
have suggested a pro-oxidant role for Cp in the etiology of cardiovascular 
disease and diabetes (124-129). Further evidence is needed to support these 
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hypotheses.  
 
On the other hand, the importance of Cp activity as a ferroxidase in hypoxia has 
been well described (130-132). Hypoxia is a serious condition that threatens cell 
survival, and can cause severe organ damage and injury in human disease (133-
138). Among the physiologic responses to hypoxia is the stimulation of 
erythropoiesis, or the increase in the O2-carrying capacity in the circulation via an 
increase in the number of circulating erythrocytes (139-142). This process 
stimulates hemoglobin synthesis, and thus elevates the demand for iron 
incorporation into heme (130-132). The increased demand for iron by 
erythrocytes is met by an efflux of iron from macrophages, which can store large 
amounts of iron due to their ability to phagocytose senescent red blood cells and 
to recycle the iron bound to hemoglobin (130-132). The export of iron from 
macrophages occurs via the ferroportin protein, and requires the oxidation of 
Fe2+ to Fe3+ by the ferrroxidase ceruloplasmin (130-132). The importance of the 
role of ceruloplasmin in iron efflux is underlined in humans and animals affected 
by a lack of ceruloplasmin (aceruloplasminemia) that results in the inability to 
export iron from tissues, and causes iron overload in parenchymal tissues, in the 
liver, and in the brain, often leading to severe neurological disorders (143, 144). 
Because ceruloplasmin is a copper-dependent protein, copper deficiency limits 
the incorporation of copper into the enzyme in the secretory pathway, and results 
in anemia due to decreased iron efflux to the circulation. Therefore, in the face of 
elevated demand for iron in the circulation, it is not surprising that relative oxygen 
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depletion or hypoxia induces ceruloplasmin expression in macrophages and 
other cell types (145, 146), as well as enhances its ability to oxidize Fe, thus 
allowing iron export via the ferroportin protein (147, 148). 
 
Interestingly, although Cp carries ∼95% of plasma Cu, and is a preferred 
substrate for non-hepatic tissues, the lack of ceruloplasmin protein or 
aceruloplasminemia in human patients does not compromise Cu-dependent 
enzyme activities (144, 149). This suggests that other Cu-binding proteins such 
as albumin can compensate for the lack of Cp and maintain copper transport and 
distribution to peripheral tissues. The copper taken up in peripheral tissues is 
mostly recycled within cells, and its turnover rate is slow. Excess Cu is released 
back into the circulation via ATP7A or ATP7B and recycled in the liver (150).  
 
 
1.7 Distribution of copper in mammalian cells 
 
 
 
Three regulated processes contribute to maintaining intracellular copper 
homeostasis, namely, Cu uptake, intracellular Cu distribution and storage, and 
Cu export (Fig. 1.2). The CTR1 protein is the major copper importer in 
mammalian cells, and serves to shuttle copper through the plasma membrane 
from the extracellular space into the cell cytosol (151). Following its translocation 
into the cytoplasm, copper is immediately sequestered and bound to small 
cytoplasmic proteins known as copper chaperones. It has been suggested that, 
in eukaryotes, cytoplasmic copper does not exist in the free unbound form (152). 
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The cytoplasm offers a reducing environment where Cu1+ can readily interact 
with hydrogen peroxide (H2O2) via the Fenton reaction to produce the highly 
reactive hydroxyl radical (OH•) (153-155). Because of its potential to enhance the 
generation of oxidative stress, Cu is quickly delivered and bound to three known 
copper chaperones ATOX1, CCS, and COX17 which in turn deliver the Cu to the 
ATP7A copper transporter, to Cu/Zn superoxide dismutase (SOD1) and to 
mitochondrial cytochrome c oxidase, respectively (156-159) (Fig. 1.2). Excess 
copper is exported via copper-dependent trafficking of ATP7A to the plasma 
membrane (Fig. 1.2).  
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FIGURE 1.2. Mammalian cellular copper homeostasis. Copper uptake occurs 
via the copper importer CTR1. Copper is then bound to the copper chaperones 
Cox17, CCS and ATOX1, which deliver copper to cytochrome c oxidase, Cu/Zn 
superoxide dismutase (SOD1), and Menkes (ATP7A) protein, respectively. The 
ATP7A protein resides mainly in the trans-Golgi network (TGN) and delivers 
copper to copper-dependent enzymes like ceruloplasmin (Cp). Elevated copper 
levels stimulate the endocytosis of the Ctr1 and the trafficking of ATP7A to the 
plasma membrane. Together, Ctr1 and ATP7A function as the key regulators of 
mammalian cellular copper homeostasis. Both proteins are ubiquitous except in 
the liver where ATP7A is not expressed, and the Wilson protein (ATP7B) 
functions in copper export (not shown). 
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Fig. 1.2 
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1.7.1 Copper uptake. 
 
 
 
Copper import into eukaryotic cells occurs via the specific high-affinity Cu 
transporter CTR1 (151). CTR1 is an integral membrane protein that is structurally 
and functionally conserved from yeast to humans (94, 160, 161). In biological 
molecules, Cu atoms show high binding affinity to histidine nitrogen, cysteine 
sulfur, and methionine sulfur. The CTR1 polypeptide contains three 
transmembrane domains, a methionine-rich N terminus, two cysteine-histidine 
motifs in the C terminus and a methionine-containing MX3M motif in the second 
transmembrane domain (162). Mutagenesis and functional studies of yeast and 
human CTR1 have shown that the MX3M motif in the second transmembrane 
domain is essential for Cu uptake, and may serve as a Cu ligand during the 
transport of Cu across the plasma membrane (162). On the other hand, the N-
terminal methionine-rich motifs are dispensable under Cu-replete conditions, but 
essential under copper-limiting conditions, suggesting that these sequences 
function in scavenging copper ions when extracellular copper levels are low 
(162). 
 
Genetic and biochemical studies of yeast and human CTR1 suggest that this 
protein can form homotrimeric complexes (93, 163). Indeed human CTR1 
(hCTR1) resolves as a 35-kDa and a 70-kDa band on non-reducing 
polyacrylamide gels, and as a 110-kDa complex when treated with crosslinking 
agents in vitro, suggesting that these bands represent the monomeric, dimeric 
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and trimeric forms of the protein, respectively. Recent two-dimensional 
crystallography and electron microscopy studies confirm that CTR1 is present as 
a homotrimer on the plasma membrane. This configuration of the protein is 
thought to form a pore or channel of nine transmembrane domains that would 
allow the passage of Cu ions across the lipid bilayer (100, 163-165).  
 
Although Ctr1 is most highly expressed in the liver, its expression is ubiquitous, 
suggesting that it mediates copper uptake in all cells of the body (151, 166).  
CTR1 specifically transports Cu+1 at a Km of ∼1-5 µM in a pH-dependent manner 
(2). Copper does not regulate the mRNA levels of CTR1 in cultured cells and 
animal models. However, studies in our lab have demonstrated that elevated Cu 
levels induce the trafficking of a functional epitope–tagged version of CTR1 from 
the plasma membrane to endosomal compartments (99). The steady-state 
localization of the CTR1 protein may vary depending on cell type; it may be 
localized to the plasma membrane or to cytoplasmic vesicles (93, 167-169). In 
HEK293 and CHO cells, CTR1 is mainly localized to the plasma membrane (93, 
167-169). In response to elevated copper levels in these cell types, CTR1 
undergoes rapid endocytosis and degradation in a time- and dose-dependent 
manner, suggesting that this is a mechanism by which cells regulate high-affinity 
Cu uptake (99, 170).  
 
Another protein with homology to CTR1 is the Cu transporter CTR2 (151). In the 
yeast saccharomyces cerevisiae, CTR2 responds to Cu deficiency by releasing 
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Cu from the vacuole into the cytoplasm (171). It is possible that the mammalian 
CTR2 protein is similarly involved in the release of Cu from intracellular stores 
such as lysosomes and other compartments into the cytoplasm. Interestingly, a 
mammalian CTR2 homologue has been identified in mice and humans, and its 
function is currently not well-understood (151). Epitope-tagged mammalian CTR2 
has been localized to the plasma membrane and to the late endosome and 
lysosomes. However, the functionality of these fusion proteins has yet to be 
demonstrated, as well as the localization of endogenous CTR2. Future studies 
and genetic animal knockout models will help elucidate the role of CTR2 in 
copper homeostasis.  
 
Interestingly, recent evidence has emerged that points to a potential role for 
CTR1 in intracellular Cu trafficking. It has been suggested that, in addition to its 
role in Cu uptake at the plasma membrane, CTR1 may function in mobilizing Cu 
out of the endosomal compartment into the cytosol, where it would be available 
for binding Cu chaperones and for incorporation into Cu-dependent enzymes. 
This model is based on recent findings in mice bearing a specific knockout of 
CTR1 in the intestines (100). The knockout mice exhibited severe Cu deficiency 
in peripheral tissues, consistent with a critical role for CTR1 in dietary Cu 
absorption. Surprisingly, intestinal epithelial cells from the knockout mice 
exhibited 8- to 10-fold hyperaccumulation of Cu compared to wild type, 
suggesting alternative pathways for Cu uptake. However, despite the elevated 
levels of intracellular Cu in these cells, the activity of Cu-dependent enzymes 
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such as mitochondrial cytochrome c oxidase was depressed. It is possible that 
the accumulated copper may be trapped in the endosomal compartment owing to 
the lack of CTR1 in these cells, rendering it biologically unavailable.  
 
It is worth noting that no known genetic diseases associated with CTR1 
mutations in humans have been identified to date. This may be attributed to the 
essential function of CTR1 in mammalian embryonic development. Indeed, this is 
underscored in studies of mice carrying null mutations of CTR1, which die in 
utero due to severe copper deficiency (172). 
 
 
1.7.2 Intracellular copper pathways. 
 
 
 
1.7.2.1 Delivery of copper to Cu/Zn superoxide dismutase (SOD1).  
 
 
 
Superoxide dismutases (SODs) are a family of metalloenzymes widely 
distributed in prokaryotic and eukaryotic cells that includes the Cu/Zn SOD (or 
SOD1) (173). These enzymes catalyze the conversion of superoxide anion O⋅ to 
hydrogen peroxide (H2O2) in a two-step reaction of O⋅ with SOD. The first step 
begins with the binding of the oxidized form of the enzyme (Cu2+-bound) to O⋅, 
acquiring a proton, and releasing molecular oxygen. The reduced form of the 
enzyme (Cu+1-bound) then binds a second superoxide anion, and liberates H2O2, 
returning to its oxidized state. H2O2 immediately becomes a substrate for the 
enzymes catalase and glutathione peroxidase (174). Thus, SOD enzymes play 
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an important role in cellular defense against superoxide-mediated oxidative 
stress (175).  
 
SOD1 is a homodimeric protein located mainly in the cytosol, with a fraction 
located in the mitochondrial intermembrane space (176, 177, 178). Incorporation 
of Cu into SOD1 requires the copper chaperone for SOD1, called CCS (179, 
180). The transfer of Cu from CCS to SOD1 occurs either in the cytosol, or the 
mitochondrial IMS since SOD1 can only cross the mitochondrial membrane as an 
apo-enzyme (181). The CCS protein comprises 3 domains (domains I, II and III) 
that carry out distinct functions during the transfer of Cu to SOD1. The N-terminal 
domain I is important for the capture of Cu ions through its MXCXXC Cu-binding 
motif. Docking of CCS to SOD1 and formation of a heterodimeric complex occurs 
via binding of domain II to a homologous highly conserved region in SOD1 (182, 
183). Following the formation of this heterodimeric intermediate, Cu is transferred 
within the CCS protein from domain I to the C-terminal domain III that 
translocates the Cu ion to SOD1 (182-184). Domain III also functions in the Cu-
dependent regulation of CCS protein ubiquitination and degradation (185). The 
Cu-dependent degradation of CCS is dose-dependent and serves as an indicator 
of intracellular copper levels. Studies in the CCS knockout mouse model (CCS-/-) 
underscore the importance of CCS for SOD1 function. CCS-/- mice exhibit normal 
levels of SOD1 protein in various tissues (brain, spinal cord, muscle, liver, lung, 
heart and kidney). However, SOD1 activity is significantly lower in these animals 
compared to wild-type littermates (181).  
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Dietary copper deficiency in animals has been associated with selective and 
organ-specific regulation of SOD1 transcript, protein, and activity levels. In rats 
fed a copper-deficient diet for 4 weeks, SOD1 activity was diminished in the 
heart, despite a high expression of both mRNA and apo-protein. On the other 
hand, a decrease in SOD1 activity, as well as a decrease in transcript and 
protein levels was observed in the livers of the Cu-deficient animals. However, no 
effect of dietary copper restriction was observed on SOD1 activity or expression 
levels in the brain of the same animals (186). The outcome of this study suggests 
that dietary copper deficiency results in tissue- and organ-specific regulation of 
SOD1 expression and activity levels.  
 
Dysregulation of SOD activity has been observed in human pathologies. 
Deficiency in SOD1 activity plays a central role in the etiology of hepatocellular 
carcinoma (187). Mice deficient in SOD1 (SOD1-/-) do not show any 
abnormalities during development, however, they exhibit significantly lower life 
spans compared to wild-type mice, as well increased neoplastic changes in the 
liver (188). Additionally, cancer cells generally have diminished SOD1 activity 
(189, 190). At the other end of the spectrum of SOD1 deficiency-associated 
pathologies is amyotrophic lateral sclerosis (ALS), where mutations within the 
SOD1 gene result in “gain of function” toxicity (191-193). ALS, or “Lou Gehrig’s 
disease”, is a selective neurodegenerative disease of motor neurons in the brain 
and spinal cord in which approximately 5% of cases are caused by SOD1 
mutations. Symptoms include generalized weakness, muscle atrophy, and 
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progressive paralysis. Over 90 distinct mutations have been identified, further 
complicating the understanding of the underlying causes of this disease (194, 
195). One potential associated mechanism is H2O2-mediated cell damage and 
toxicity caused by excess mutant SOD activity (191, 196). 
 
 
1.7.2.2 Copper delivery to the mitochondria.  
 
 
 
The mitochondrial respiratory complex IV enzyme cytochrome c oxidase (CCO) 
is a Cu-dependent integral membrane protein complex of the mitochondria 
involved in respiration and ATP synthesis. CCO is the only respiratory complex 
that requires copper for its function (197). The CCO complex is comprised of 13 
subunits, with 3 of them (COX1-COX3) forming the core of the enzyme being 
encoded by the mitochondrial genome (197). COX1 and COX2 also constitute 
the copper-binding subunits of CCO, with 1 Cu atom incorporated into the CuB 
site of COX1, and 2 Cu atoms incorporated into the CuA site of COX2 (197). 
Since COX1 and COX2 are encoded by the mitochondrial genome, copper 
metallation must occur within the organelle. The only other known copper-
dependent protein within the mitochondrion is SOD1, localized in the IMS. As 
previously mentioned, SOD1 enters the mitochondrion in its apo-form, and 
receives its copper within the IMS (178). The presence of 2 metalloenzymes that 
are metallated within the mitochondrion requires copper transport into this 
organelle. While CCS chaperones Cu into the mitochondrial IMS for incorporation 
into SOD1 (182), the Cu chaperone COX17 is required for the delivery of Cu to 
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CCO through a complex series of events (198). Although COX17 is present in 
both the cytosol and the mitochondrial IMS, it is not an obligate mitochondrial 
copper chaperone (197, 199). This was demonstrated in experiments tethering 
COX17 to the IMS by a heterologous IM-binding domain, which resulted in the 
exclusive localization of COX17 to the mitochondria. In these experiments, 
tethered COX17 reversed the respiratory defect of cox17Δ yeast cells and 
restored CCO activity (200). Additionally, cox17Δ cells contained mitochondrial 
Cu levels similar to wild type. Exactly how Cu makes its way from CTR1 at the 
plasma membrane into the mitochondrion is still unclear. The inability of CCS to 
overcome COX17 deficiency even when overexpressed at supraphysiological 
levels suggests the presence of one or more alternative molecules that shuttle 
Cu from the cytosol into the mitochondrion (96). Recently, a small Cu ligand has 
been identified in the cytosol and the mitochondrial matrix of yeast and mouse 
liver extracts (199, 201). Future studies will aim at understanding the potential 
role of this ligand in intracellular copper homeostasis. 
 
The incorporation of Cu into CCO is a multi-step event that is not well understood 
and is the subject of ongoing studies. Evidence suggests that insertion of Cu into 
the CuB site of COX1 occurs via a transfer of Cu from COX17 to the integral 
membrane COX11 protein, which facilitates the insertion of Cu into COX1 (199, 
201). Two additional metallochaperones have been identified, SCO1 and SCO2 
that assist in the incorporation of Cu into the CuA site of COX2 (202-205). 
Another Cu-binding protein, COX19, localized to the IMS and structurally similar 
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to COX17, has been suggested as an additional player in the incorporation of Cu 
into CCO (206). 
 
Although the pathways of Cu delivery into the mitochondrion and CCO are not 
well understood, the significance of this topic is underscored by inherited 
deficiencies in CCO in humans with mutations in copper assembly proteins. In 
yeast, mutations in the cox17 gene result in a respiratory defect owing to a lack 
of CCO activity, since CCO depends on Cu for its activity (156, 198, 207). 
Additionally, COX17 knockout mice die in utero, revealing an essential role for 
COX17 in embryonic development (208). Recent studies in patients carrying 
mutations in either SCO1 or SCO2 revealed that liver, heart and skeletal muscle 
samples contained significantly lower amounts of copper compared to tissues 
from control subjects (209). Significantly, this effect was associated with 
increased copper efflux via the ATP7A protein. The authors also showed that this 
effect was independent of defects in CCO assembly, suggesting a novel role for 
the SCO1 and SCO2 proteins in the regulation of copper homeostasis via a 
mitochondrial signaling pathway.  
 
 
1.7.2.3 Delivery of copper to the secretory pathway. 
 
 
 
The transport of Cu from the site of CTR1-mediated uptake at the plasma 
membrane to the secretory pathway occurs via the Cu chaperone ATOX1. In the 
cytosol, ATOXI delivers Cu to one of two Cu-ATPases, ATP7A known as Menkes 
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protein, or ATP7B or Wilson protein, which in turn actively transport Cu into the 
TGN. Delivery of Cu to the secretory pathway allows its incorporation into 
cuproenzymes, as well as regulates its trafficking-mediated export when 
intracellular Cu levels are in excess. 
 
 
1.7.2.3.1 The copper chaperone ATOX1. 
 
 
 
ATOX1, also known as HAH1, is a cytosolic protein that plays a key role in 
delivering Cu to ATP7A and ATP7B (70, 110). Deletion of the ATOX1 gene in 
mice results in intracellular copper accumulation and a decrease in the activity of 
Cu-dependent enzymes (210), suggesting deficient Cu-ATPase transport activity. 
Furthermore, the offspring of ATOX1 knockout mice suffer growth retardation, 
hypopigmentation and skin laxity phenotypes and increased perinatal mortality 
similar to Menkes patients (210), owing to impaired transfer of Cu from the 
placenta to the embryo.  
 
Yeast Atx1 was originally identified as a small antioxidant protein that 
suppressed oxygen toxicity in yeast mutants lacking SOD1. Atx1 was 
subsequently shown to be a copper chaperone (211). Shortly following this 
discovery, a homologue in humans and other mammals was identified and 
named ATOX1 (212). The yeast Atx1 has been shown to facilitate the function of 
the P-Type Cu-ATPase Ccc2, which transports copper into the late Golgi 
compartment (213). Mammalian ATOX1 is a small cytosolic protein with striking 
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structural homology to the metal-binding domains (MBD) of the Cu ATPases  
(214). ATOX1 contains a single repeat of the MXCXXC Cu-binding domain, and 
this MBD has been shown to bind one Cu1+ molecule (215). Both ATP7A and 
ATP7B carry 6 repeats of the MBD in their N-terminal regions, and, as in ATOX1, 
each of these MBDs binds a single Cu1+ molecule. The MBDs are thought to play 
a critical role in the direct interaction between ATOX1 and the ATPases during 
the Cu transfer process. In vitro, Cu-ATOX1 has been demonstrated to transfer 
Cu directly to the MBDs of ATP7B in a dose-dependent manner (215-219). All 6 
sites on the ATP7B protein can be filled via this interaction; however, a significant 
excess (5- to 50-fold) of ATOX1 over ATP7B is needed to achieve complete 
saturation of the N-terminal MBDs. In vitro studies in embryonic fibroblasts from 
ATOX1 knockout mice show that ATOX1 plays an important role in the Cu-
induced trafficking of ATP7A (158).  
 
 
1.7.2.3.2 The Cu-ATPase ATP7A or Menkes protein. 
 
 
 
The Menkes protein is encoded by the ATP7A gene and is expressed in most 
mammalian tissues expect the liver (43-45, 220). This copper transporter 
contains eight membrane-spanning domains and six cysteine-rich copper binding 
sites at the amino terminal region that are required for high affinity copper 
transport. ATP7A belongs to the P-type ATPase family whose members utilize 
the energy derived from ATP hydrolysis to transport cations (221). During each 
catalytic cycle, which results in the transport of Cu, the ATP7A protein undergoes 
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rapid auto-phosphorylation at a conserved aspartic acid residue, followed by de-
phosphorylation to complete the cycle (222, 223). As discussed above, Menkes 
disease is a lethal genetic disease caused by mutations in the ATP7A protein, 
and is characterized by overall copper deficiency and severe pathophysiological 
consequences such as neurological impairment, convulsions, connective tissue 
abnormalities, skin laxity and hypopigmentation (46). These mutations in the 
ATP7A protein result in the reduced efflux of copper from cells (224), and the 
inability of the ATP7A MNK protein to transport Cu across the enterocytic 
basolateral membrane into the bloodstream. Mutations in the ATP7A protein may 
affect its copper transport activity and/or its ability to traffic to the plasma 
membrane (169, 225-228). Menkes disease is primarily a defect in copper efflux. 
Skin fibroblasts, lymphoblasts and amniocytes isolated from human Menkes 
patients and cultured in vitro accumulate copper in essential medium without 
additional copper. Thus, mutations in the ATP7A protein disrupt normal cellular 
copper homeostasis (221, 229, 230). 
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FIGURE 1.3. Menkes protein traffics in response to copper in cultured 
human fibroblasts. A, Topology of the ATP7A protein. B, Copper treatment of 
cultured fibroblasts induces the relocalization of ATP7A from the trans-Golgi 
network (TGN) to post-Golgi vesicles and the plasma membrane. This process 
results in the net export of copper and prevents the accumulation of potentially 
toxic excess copper. Immunofluorescence labeling of the ATP7A protein is 
shown in green. The nucleus is stained red with propidium iodide.  
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Fig. 1.3  
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The steady-state subcellular localization of the ATP7A protein is within the final 
compartment of the Golgi apparatus, also known as the trans-Golgi network 
(TGN) (1, 231). ATP7A transports copper from the cytoplasm across the Golgi 
membrane and delivers it to copper dependent enzymes within the TGN (232-
237). The subcellular localization of ATP7A is regulated by copper (Fig. 1.3). In 
response to elevated copper levels in the cytoplasm, the ATP7A protein traffics 
within post-Golgi vesicles to the plasma membrane (1, 169, 238, 239). The 
copper-stimulated trafficking of ATP7A is a defense mechanism that protects the 
cell from excess copper toxicity. However, ATP7A mRNA and protein levels in 
cultured cells and mouse tissues do not change in response to copper availability 
(1, 240). Consistent with its role in transporting copper into the bloodstream from 
enterocytes and kidney tubules, and into the central nervous system across the 
blood brain barrier, the ATP7A protein traffics to the basolateral membrane in 
response to elevated copper concentrations in cultured polarized epithelial cells 
(241). 
 
 
1.7.2.3.3 Mutational analyses of copper-stimulated ATP7A protein 
trafficking. 
 
 
Previous studies have demonstrated that the trafficking of ATP7A is dependent 
on copper-binding sites closest to the first membrane-spanning domain (228). 
Studies in our laboratory have demonstrated that mutations that prevent the 
formation of the phosphorylated catalytic intermediate of the ATP7A protein also 
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block the ability of the protein to traffic in response to copper (169). Moreover, 
certain Menkes disease mutations, including the mutation in the Brindled mouse, 
totally abolish the trafficking of ATP7A in response to elevated copper (225, 226, 
242). Based on these findings, it is suggested that the catalytic activity of ATP7A 
is essential for its trafficking function (169). However, catalysis is not a 
prerequisite for trafficking since our laboratory has identified a mutation that 
blocks the trafficking response but does not inhibit normal copper transport 
activity into the Golgi (226).  
 
 
1.7.2.3.4 Mouse models of Menkes disease. 
 
 
 
The murine model of Menkes disease is a collection of mice called the “mottled” 
mice. Each mottled mouse variant is caused by a mutation in the X-linked 
mottled gene (Atp7aMo or Mnk), which is the orthologue of the human ATP7A 
gene (243-250). These mutations block copper transport activity of the ATP7A 
protein, as evidenced by the accumulation of copper in cultured fibroblasts from 
mottled mice (242, 251). The mottled mice have considerable phenotypic 
variability, however, each mutant exhibits symptoms of copper deficiency similar 
to the human disease. For example, the Brindled mouse, a model of the classical 
disease in humans (243), carries an in-frame deletion of two codons resulting in 
the deletion of two amino acids in a cytoplasmic loop of the ATP7A protein (243). 
This mutation inhibits copper transport to cuproenzymes and copper-stimulated 
trafficking, despite the normal localization of the ATP7A protein in the TGN (227, 
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252). Brindled mice usually die within three weeks of birth, but this can be 
prevented by a single subcutaneous copper injection (50 µg) administered within 
10 days of birth (234, 253-256). The timing of this injection is critical, since 
treatments that are delayed beyond the 10th day do not extend life expectancy. 
The copper injections have been shown to correct the neurological symptoms, 
such as tremors and spasms seen in untreated mutants (234), and to rescue 
some of the copper deficiency in peripheral tissues, although liver copper levels 
remain below normal (254, 256). In contrast to wild type mice in which copper 
injections have no lasting effect on organ copper levels (234, 253, 254), the 
copper-treated brindled mice exhibit patterns of Cu maldistribution similar to 
those seen in Menkes patients, including above-normal copper levels in 
enterocytes and kidneys, and reduced levels in serum and the liver. Interestingly, 
macrophages from the copper-treated Brindled mouse also accumulate copper 
(254). Although the growth of copper-rescued Brindled mice is significantly 
retarded in the first weeks of life, these animals reach normal weight by 60 days 
of age (234).  
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1.8 Copper homeostasis during the inflammatory response. 
 
 
 
Infection or tissue injury promotes a variety of inflammatory responses. 
Monocytes accumulate at the site of inflammation where they differentiate into 
macrophages. Macrophages and other phagocytes, such as neutrophils, ingest 
microbes into the phagosome, which is accompanied by a toxic “respiratory 
burst” of superoxide (257). Other products of the respiratory burst include 
hydrogen peroxide and the hydroxyl radical (258-260). These processes are part 
of the innate immune response. Interestingly, the acute phase response to 
infections and inflammation in humans and animals is marked by changes in 
circulating metal levels. Both zinc and iron levels are significantly decreased, 
resulting the classical hypozincemia and hypoferremia, two hallmark events of 
the acute-phase response (261, 262). In contrast, inflammation results in an 
increase in copper levels in the serum, or hypercupremia (263-274). 
Ceruloplasmin is an acute phase protein, and the rise in serum copper levels 
during inflammation may be partially attributed to increased circulating holo-Cp 
levels (120). Indeed, it has been shown that inflammation also promotes the 
accumulation of the non-protein bound fraction of copper in the serum (263). 
Radiotracer studies with 64Cu have demonstrated that copper accumulates at 
sites of inflammation (275), and within the exudates of wounds and burns relative 
to serum (276, 277).  
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Unlike copper, iron and zinc levels in the serum are reduced during inflammation, 
presumably to starve microbes of these essential nutrients. The expression of the 
zinc importer ZIP14 is elevated in the liver during inflammation. This is thought to 
increase zinc uptake into the liver and lowers its concentration in the serum 
(278). In the case of iron, the decrease in serum iron levels may be attributed to 
regulation by the peptide hormone hepcidin, which is secreted from the liver 
during inflammation. Hepcidin has been shown to trigger the endocytosis and 
reduced expression of the iron exporter ferroportin-1 in enterocytes and 
macrophages (116, 279), thus reducing the transport of dietary iron into the blood 
and the export of iron from macrophages of the reticuloendothelial system. These 
responses are among several others that function to limit iron as a nutrient for 
microbial growth (280). 
 
 
1.8.1 Copper is a bactericidal agent. 
 
 
 
Mild copper deficiency has been associated with impaired function of neutrophils 
and macrophages (281-284). Moreover, in cultured peritoneal macrophages, 
phagosomal copper levels are increased ten-fold when cells are infected with 
Mycobacterium avium in the presence of the cytokine IFN-gamma (285). Thus, 
copper levels may become elevated in the serum during inflammation to promote 
anti-microbial functions of these phagocytic cells. Consistent with this hypothesis, 
evidence suggests that the ability of pathogenic bacteria to export copper 
influences their virulence in the host. The virulence of Pseudomonas aeruginosa 
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is severely decreased (20-fold) by mutations in the copper exporter, CueA (286), 
and a similar attenuation of pathogenicity occurs in Listeria monocytogenes 
carrying a mutation in the copper exporter, CtpA (287). Also, the expression of 
several metal ion exporters including two putative copper efflux transporters, 
CopA1 and CopA2, are induced in Legionella pneumophila upon phagocytosis by 
macrophages (288).  
 
Copper owes its bactericidal activity to its ability to transition between Cu1+ and 
Cu2+. This property of the copper ion allows it to participate in the Fenton 
reaction, whereby hydrogen peroxide H2O2 is quickly converted to the highly 
reactive hydroxyl radical OH• (153-155). Reactive oxygen species (ROS), and 
more specifically OH• greatly contribute to the killing of bacteria within the 
phagosomal compartment of immune cells. OH• is highly toxic to cells due its 
ability to react with and oxidize organic molecules, such as membrane lipids, 
proteins and DNA, thereby compromising membrane fluidity and other essential 
cellular functions (289). It is not surprising, therefore, that phagocytic cells of the 
immune system have harnessed this property of ROS, and use it as a first line of 
attack against pathogens within the phagosomal compartment. This is known as 
the respiratory or oxidative burst, and it occurs in phagocytic cells as they initiate 
the degradation of internalized pathogens (257). 
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1.9 A role for copper in the cellular response to hypoxia. 
 
 
 
1.9.1 Physiological and cellular responses to hypoxia. 
 
 
 
Oxygen (O2) utilization by cells of the body normally serves to regenerate energy 
in the form of ATP. Hydrolysis of ATP provides the necessary energy for 
maintenance, self-repair and for sustenance of tissue- and organ-specific 
functions. Although cells have a limited ability to generate ATP in the absence of 
O2 via anaerobic respiration, the loss of O2 supply, even for a short period of 
time, can threaten cell survival. Therefore, organisms have developed a number 
of adaptive responses to defend the O2 supply in response to environmental 
changes, or to diseases that decrease the delivery of O2 to tissues. Specialized 
O2-sensing systems have evolved to detect subtle changes in O2 tension. Among 
these are the arterial chemoreceptors that monitor O2 levels in the blood and 
signal to the respiratory system to increase the levels of alveolar ventilation when 
arterial O2 tension is too low. The liver and kidneys secrete erythropoietin, a 
hormone that signals to increase the number of circulating erythrocytes and the 
O2–carrying capacity in the circulation (139). In addition, cells protect themselves 
during limitations in O2 supply by downregulating O2 utilization (140-142).  
 
Rapid responses are required on the cellular level in order to protect the cell from 
prolonged O2 depletion. These responses are mediated by the hypoxia-inducible 
factor transcription factor (discussed below), and lead to the upregulation of 
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genes involved in glucose uptake, cell survival, cytoskeletal organization, 
extracellular matrix remodeling, cell adhesion, vascular tone, iron metabolism, 
and apoptosis (290-294). On the physiological level, responses to limitations in 
O2 supply ultimately result in vascular remodeling, formation of new blood 
vessels or angiogenesis, and cell migration and proliferation. 
 
 
1.9.2 Transcriptional responses to hypoxia.  
 
 
 
Hypoxia, or low oxygen tension, is a common feature of many solid tumors (295), 
and has also been implicated in the etiology and the progression of Alzheimer’s 
disease (296). In cancer, hypoxia has been linked to malignant transformation, 
metastasis, and treatment resistance (295). The cellular adaptation responses to 
hypoxia are mediated via the hypoxia-inducible factor 1 (HIF-1), a transcription 
factor often named “the master regulator of hypoxic responses”, that upregulates 
hypoxia response element- (HRE-) dependent gene expression. Among HRE-
dependent genes are several genes involved in glycolytic energy metabolism, 
angiogenesis, cell survival and erythropoiesis. Some of these are glucose 
transporters (GLUT), vascular endothelial growth factor (VEGF), erythropoietin, 
and other glycolytic genes (297, 298). 
 
HIF-1 is a heterodimer composed of two subunits, an oxygen-regulated α subunit 
(HIF-1α) and a constitutively expressed β subunit (HIF-1β), both of which are 
ubiquitously expressed in mammalian cells (299). The HIF-1 complex regulation 
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is dependent on the stability of the HIF-1α subunit. HIF-1α is constitutively 
expressed; however, under normoxic conditions, the protein undergoes 
ubiquitination and is targeted for proteosomal degradation (300, 301). This 
involves the binding of the von Hippel-Lindau tumor suppressor protein (VHL) to 
an oxygen-dependent degradation domain on the HIF-1 protein. The binding of 
VHL to HIF-1α is regulated via hydroxylation of key proline residues on the HIF-1 
protein, which is carried out by a family of HIF prolyl hydroxylases (HIF-PHs) 
(108, 302-304). HIF-PHs require oxygen and iron binding for their activity. Thus, 
during hypoxia, or in the presence of iron chelators such as desferrioxamine 
(DFO) or iron-displacing metals such as cobalt, HIF-PHs are inactivated, and this 
leads to a stabilization and accumulation of the HIF-1α protein. Thus, HIF-1 acts 
as a sensor of cellular oxygen tension and iron homeostasis in all cell types.  
 
HIF-1 activation in cancer cells is highly associated with cell growth and survival, 
tumor development, tumor angiogenesis and poor clinical prognosis (305-308). 
Histopathological studies in primary tumors of the breast, colon, brain, lung, 
ovary and prostate have detected HIF-1 expression that could not be seen in 
corresponding normal tissues (308). Although hypoxia is the ubiquitous inducer 
of HIF-1 expression, constitutive HIF-1 expression has been detected in several 
nonhypoxic cancer cell lines (305) and normal tissues (309). In fact, in several 
cell types, other stimuli have been reported to stabilize and activate HIF-1, 
including epidermal growth factor (EGF), insulin, insulin-like growth factor 1 (IGF-
1), angiotensin II and others (310-312). Altogether, these observations suggest a 
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role for distinct signaling mechanisms in the regulation of HIF-1 activity. Of 
relevance here are the effects of copper and mitochondrially-generated reactive 
oxygen species on HIF-1 expression.  
  
 
1.9.3 Cu- and ROS-mediated activation of HIF-1 and HRE-dependent genes.  
 
 
 
Transition metals have long been used as molecular mimics of hypoxia. Co2+, 
Ni2+ and Mn2+ salts induce the expression of erythropoietin in the hepatoma cell 
lines HepG2 and Hep3B under normoxic conditions (313). CuCl2 also stabilizes 
HIF-1 under normoxic conditions and stimulates the expression of HRE-
dependent genes. Martin et al. (314) have suggested that copper activates HIF-1 
by inhibiting prolyl hydroxylase activity independent of iron availability. Their 
experiments in hepatoma cells suggest that both copper and hypoxia increase 
the ceruloplasmin, VEGF and GLUT-1 mRNA levels. The authors propose that 
HIF-1 activation and HRE-dependent gene regulation not only serves as a 
sensing system for oxygen tension and iron availability, but also regulates copper 
metabolism.  
 
The mechanism by which copper and other transition metals regulate HIF-1 is 
unknown. Several studies have implicated reactive oxygen species (ROS) in 
transition-metal dependent HIF-1 activation (315-319). As a transition redox 
metal, copper can participate in Fenton reactions, thereby catalyzing the 
conversion of molecular oxygen (O2) into the powerful oxidant superoxide (O•). In 
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the cellular environment, superoxide is rapidly converted to hydrogen peroxide 
(H2O2) by superoxide dismutase (SOD). Copper then catalyzes the conversion of 
hydrogen peroxide into the harmful hydroxyl radical (OH•) (154, 155).  
 
Increasing evidence suggests that it is the accumulation of ROS produced mainly 
by the mitochondria during low oxygen tension that mediates the activation of 
HIF-1. In particular, H2O2 has been linked to the stabilization of HIF-1 and the 
induction of HRE-dependent genes during hypoxia (139, 320-323). Grzenkowicz-
Wydra et al. (323) have shown that overexpression of the human Cu/Zn 
superoxide dismutase SOD1 in NIH3T3 fibroblasts leads to enhanced 
intracellular production of H2O2 and stimulation of VEGF synthesis. In their study, 
H2O2 increased VEGF promoter activity, VEGF mRNA expression and VEGF 
protein synthesis. This effect was blocked by the simultaneous overexpression of 
catalase, an enzyme involved in antioxidant defense that scavenges H2O2 and 
converts it to H2O. This is supported by further evidence that the overexpression 
of the antioxidants catalase and glutathione peroxidase during hypoxia prevents 
the stabilization of HIF-1α (324, 325). 
 
It has been suggested that ROS stabilize HIF-1 indirectly via activation of kinase 
signaling cascades. Three pathways have been identified that can be activated 
by ROS, and in turn activate HIF-1. These are small GTPases (such as Rac or 
Rho), c-Src kinase, and p38a MAPK (326-328). However, the direct mechanisms 
by which ROS activate these signaling pathways that ultimately stabilize HIF-1α 
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during hypoxia have not been determined yet. In summary, it is possible that 
copper activates HIF-1 directly by binding and inhibiting the HIF-prolyl 
hydroxylases, and indirectly via its redox potential to generate ROS.  
 
 
1.9.4 Generation of ROS during hypoxia.  
 
 
 
Relative O2 depletion can cause severe organ damage in human disease. 
Hypoxic tissue injury occurs during respiratory failure, systemic hypotension, and 
regional hypoperfusion of organs. Reactive oxygen species have been implicated 
in the lethal cell injury resulting from relative hypoxia and following reperfusion of 
ischemic heart, brain and organs (329-332). Studies have also shown that severe 
high-altitude hypoxia can increase the generation of cellular oxidative stress, thus 
causing damage to lipids, proteins and DNA (133-138).  
 
Several cellular mechanisms for O2-sensing and generation of ROS during 
hypoxia have been investigated, including NADPH oxidase (333) and 
cytochrome p450 (334). Diphenyleneiodonium (DPI) is a non-specific inhibitor of 
flavoprotein oxidases. DPI interferes with HIF1-mediated responses to hypoxia 
(335). Thus, it has been concluded that NADPH oxidase and/or cytochrome p450 
regulate O2 sensing and participate in HIF-1 activation during hypoxia (336). 
However, DPI also inhibits mitochondrial complex I (337). Inhibition of complex I 
suppresses ROS production by complex III (see below for further discussion; 
reviewed in (139)). Moreover, in B cell lines deficient in either the p22phox or the 
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gp91phox subunits of the NADPH oxidase, the VEGF and aldolase mRNA 
responses to hypoxia are intact, suggesting that O2-sensing mechanisms 
independent of NADPH oxidase exist (321, 338). The roles of NADPH oxidase 
and cytochrome p450 certainly require further investigation.  
 
 
1.9.5 Mitochondrial ROS production regulates the responses to hypoxia. 
 
 
 
Mitochondria are classically considered the subcellular organelles in eukaryotes 
that are responsible for energy production. Mitochondria consume oxygen and 
generate the ATP required for energy utilization, thus O2 deprivation threatens 
cell survival. Recent emerging evidence now implicates mitochondria as a major 
source of free radicals, and as the source of signaling that regulates cell cycle, 
proliferation, and apoptosis. In 1973, Boveris and Chance described the 
production of H2O2 by mitochondria, and characterized H2O2 as a by-product of 
the auto-oxidation of components of the respiratory electron transport chain 
(339). This process, the “electron leak”, occurs during respiration under 
conditions of sufficient O2 supply.  
 
New evidence now points to the mitochondria as the site of O2 sensing during 
hypoxia. It has been proposed that the electron transport chain senses 
decreases in O2 supply and produces ROS in response to hypoxia. The ROS 
released from the mitochondria act as signaling molecules and activate HIF-1 
(139, 321, 324, 325, 340-344). The importance of mitochondrial signaling in the 
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cellular responses to hypoxia is emphasized by studies using ρ0 cells which have 
been depleted of their mitochondrial DNA. ρ0 cells lack mitochondrial DNA-
derived proteins and are therefore deficient in key components of the electron 
transport chain, which renders them incapable of mitochondrial respiration (321). 
Contrary to wild-type cells, ρ0 cells fail to stabilize HIF-1-dependent gene 
expression as well as fail to produce ROS during hypoxia (321, 340).  
 
It is now widely accepted that ROS production during hypoxia primarily originates 
at complex III of the respiratory chain. Eukaryotic complex III is an assembly of 
11 proteins encoded by nuclear and mitochondrial genes (345). Complex III 
accepts electrons from ubiquinol, and transfers these to cytochrome c. The Q 
(Ubiquinone) cycle is a major component of complex III. A pair of electrons is 
transferred to ubiquinone from complexes I and II. This yields ubiquinol. As 
cytochrome c and cytochrome c oxidase (CCO) accept single electrons 
sequentially, the Q cycle within complex III converts the paired transfers of 
complexes I and II into the sequential transfers needed for complex IV (346). 
This sequential transfer of electrons at complex III temporarily yields the 
univalently reduced ubisemiquinone. The relatively unstable ubisemiquinone 
radical is repeatedly generated at complex III during the electron transport 
process. Molecular O2 within the mitochondrial membrane can potentially capture 
the electron from ubisemiquinone, yielding superoxide. The probability of this 
event occurring increases as the lifetime of the ubisemiquinone radical increases 
(342-344) . Mitochondrial inhibitors, such as Antimysin A, which increase the 
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half-life of ubisemiquinone, increase superoxide production at complex III (339). 
Genetic evidence for the requirement of complex III in the cellular responses to 
hypoxia is provided by studies using RNA interference against the Rieske 
protein. The Rieske protein is a subunit of complex III that plays a central role in 
generating ubisemiquinone during the electron transfer process. siRNA knockout 
of the Rieske protein prevents the formation of ubisemiquinone, and significantly 
attenuates ROS production compared to controls. Significantly, siRNA against 
the Rieske protein prevents the stabilization of HIF-1α during hypoxia (324, 325).  
 
 
1.10 Potential role for copper in human disease. 
 
 
 
The importance of copper as a nutrient has been underlined in this review. In 
addition to illnesses directly related to defects in the various copper homeostatic 
pathways, new connections have been drawn between copper and disease 
conditions such as inflammation, angiogenesis, and Alzheimer’s disease. 
Inflammation is accompanied by an increase in serum copper levels (263-267), 
and copper has been shown to play a role in the proper functioning of the 
immune system (281-284).  
 
A hallmark of many chronic inflammatory illnesses such as cancer, Alzheimer’s 
disease, atherosclerosis and others is a decrease in the availability of oxygen at 
the site of inflammation. This lower-than-normal oxygen tension induces a wide 
array of cellular and physiological responses, including an increase in oxidative 
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stress in the inflammatory milieu, and the formation of new blood vessels along 
with the restructuring of the surrounding extracellular matrix. Copper availability 
during low oxygen tension may influence the outcome of such cellular and 
physiological processes and may tip the balance towards either the resolution or 
the exacerbation of the disease condition.  
 
Angiogenesis, or the process of new blood vessel formation, serves to provide 
nutrients and oxygen to tissues where blood flow has been obstructed, and is an 
important component in the mechanism of tumor growth and metastasis. Copper 
is essential for the angiogenic process, not only in the cross-linking of newly 
formed extracellular matrix, but also in the transcriptional regulation of certain 
angiogenic responses. Copper chelation therapy has been successfully used in 
animal trials in the inhibition of angiogenesis in cancer (347-352). Copper is also 
an important component of Aβ plaques, as it serves to cross-link and aggregate 
the Aβ protein in the extracellular milieu, thus rendering it toxic to surrounding 
neurons (353-357).  
 
Despite the emerging knowledge of a role for copper in these disease conditions, 
very little is understood about the role and contribution of the major regulators of 
copper homeostasis, CTR1 and ATP7A, in these pathophysiological events. The 
goal of my studies is two-fold: 1) To investigate the changes in copper 
homeostasis in macrophages during inflammation and gain an understanding of 
the contribution of these changes to the bactericidal activity of this cell type. 2) To 
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investigate the effect of hypoxia on the copper homeostatic pathways in 
macrophage cells and gain some insight into the potential regulatory role of 
oxidative stress in governing these cellular adaptations.  
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CHAPTER 2 
 
 
 
A ROLE FOR THE ATP7A COPPER TRANSPORTING ATP7ASE IN 
MACROPHAGE BACTERICIDAL ACTIVITY 
 
 
2.1 Abstract 
 
 
 
Copper is an essential micronutrient required for healthy immune function. This 
requirement is underscored by increased susceptibility to bacterial infection in 
copper deficient animals, however, a molecular understanding of copper’s 
importance in immune defense is unknown. To elucidate the role of copper in 
innate immune function, we investigated the effect of pro-inflammatory agents on 
copper homeostasis in RAW264.7 macrophages. Interferon-gamma was found to 
increase expression of the high affinity copper importer, CTR1, and stimulate 
copper uptake. This was accompanied by copper-stimulated trafficking of the 
ATP7A copper exporter from the Golgi to vesicles that partially overlapped with 
phagosomal compartments. Silencing of ATP7A expression attenuated bacterial 
killing, suggesting a role for ATP7A-dependent copper transport in the 
bactericidal activity of macrophages. Significantly, a copper sensitive mutant of 
Escherichia coli with a defect in copper export was hypersensitive to killing by 
RAW264.7 macrophages, and this phenotype was dependent on ATP7A 
expression. Together, these data reveal a critical role for copper transport via the 
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ATP7A protein in macrophage-dependent bactericidal activity and demonstrate a 
unique role for copper in host-pathogen interactions. 
 
 
2.2 Introduction 
 
 
 
Copper is an essential nutrient for aerobic organisms. Its ability to exchange 
electrons as it cycles between cuprous and cupric states has been harnessed by 
enzymes that catalyze a wide variety of biochemical processes (96).  However, 
these same redox properties also confer copper with toxic properties when it is 
present in the free ionic form.  Free copper can participate in Haber-Weiss 
chemistry to produce the highly toxic hydroxyl radical from hydrogen peroxide 
and superoxide (2-4).  It is, therefore, not surprising that organisms have evolved 
tightly regulated mechanisms for copper transport and intracellular distribution.  
 
The importance of micronutrient intake for optimal immune function is an area of 
intense research, and several studies have demonstrated the importance of 
copper. Studies in animals fed copper-deficient diets have shown impaired 
animal resistance to a number of pathogens including Candida albicans (5, 6), 
Pasteurella haemolytica (358), Trypanosoma lewisi (359) and Salmonella 
typhimurium (9). Other studies have shown that copper supplementation is 
protective against Escherichia coli induced mastitis in dairy cattle (10). In vitro 
studies have shown that copper deficiency impairs the bactericidal activity of 
neutrophils and macrophages (11-13). Moreover, a recent study demonstrated 
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that copper concentrations are markedly increased within the phagosomal 
compartment of macrophages activated by interferon-gamma (IFN-γ) and 
Mycobacterium avium (14).    
 
The potential toxicity of copper can be attributed to its ability to transition 
between the cuprous (Cu1+) and the cupric (Cu2+) states. This property of the 
copper ion allows it to participate in the Fenton reaction, whereby hydrogen 
peroxide (H2O2) is quickly converted to the highly reactive hydroxyl radical OH• 
(153-155). Reactive oxygen species (ROS), and more specifically OH• greatly 
contribute to the killing of bacteria within the phagosomal compartment of 
immune cells (257). OH• is highly toxic to cells due its ability to react with and 
oxidize organic molecules, such as membrane lipids, proteins and DNA, thereby 
compromising membrane fluidity and other essential cellular functions (289). It is 
not surprising, therefore, that phagocytic cells of the immune system have 
harnessed this property of ROS as a first line of attack against pathogens within 
the phagosomal compartment. This is known as the respiratory or oxidative 
burst, and it occurs in phagocytic cells as they initiate the degradation of 
internalized pathogens (257). Interestingly, the acute-phase response to 
infections and inflammation in humans and animals is marked by changes in 
circulating metal levels. Both zinc and iron levels are significantly decreased, 
resulting in the classical hypozincemia and hypoferremia, two hallmark events of 
the acute-phase response to inflammation (261, 262). In contrast, inflammation 
results in an increase in copper levels in the serum, or hypercupremia (263-274, 
 58 
360-364). Collectively, these studies provide compelling evidence of a role for 
copper in innate immune defense, however, an understanding of the underlying 
processes at a molecular level is lacking. 
 
On the cellular level, mammalian copper homeostasis is maintained by the 
concerted regulation of copper uptake and copper export. The copper importer 
Ctr1 is ubiquitously expressed. It is localized to the plasma membrane and 
transports copper across the membrane into the intracellular milieu (151, 166). 
Copper export from the cytoplasm is mediated by ATP7A, also known as Menkes 
protein. In steady-state conditions, ATP7A resides in the Trans-Golgi network 
(TGN) (1, 365), and delivers copper to copper-containing proteins and enzymes 
(232-237). Under excess copper conditions, ATP7A relocates from the TGN to 
the plasma membrane where it exports copper, thus protecting the cell from 
potential copper-mediated toxicity (1). ATP7A cycles between the TGN and the 
plasma membrane as it exports copper, and returns to its TGN localization (169, 
238, 366) once steady-state copper homeostasis is re-established. CTR1 and 
ATP7A protein and mRNA levels do not respond to changes in copper 
concentrations. Overall, mammalian copper homeostasis is maintained via post-
translational regulation of the localization of the copper importer CTR1 and the 
copper exporter ATP7A. However, little is known about how these major players 
in cellular copper homeostasis are regulated during inflammation.  
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The fact that inflammation is accompanied by hypercupremia, and that copper 
exhibits bactericidal properties suggests that immune cells of the phagocytic type 
may benefit from this increased availability of copper and use it as an advantage 
to speed up the killing of pathogens. Here, we report dramatic changes in copper 
homeostasis triggered by the inflammatory response in macrophages. These 
include elevated expression of the CTR1 copper importer, increased copper 
uptake, and copper-stimulated trafficking of the ATP7A copper exporter from the 
Golgi to vesicles that overlap with the phagosomal compartment. Significantly, 
RNAi-mediated depletion of ATP7A in RAW264.7 cells reduced bactericidal 
activity, suggesting that this process was dependent on copper transport via 
ATP7A. Consistent with this role, a copper-sensitive mutant of E. coli with a 
defect in copper export was significantly more sensitive to macrophage-mediated 
killing, and this sensitivity was dependent on ATP7A expression. These findings 
reveal ATP7A-mediated copper transport as a novel determinant of macrophage 
bactericidal activity and identify a unique interplay between copper transport 
activities of host and pathogen. 
 
 
2.3 Materials and Methods 
 
 
 
Preparation of stock solutions— The stock solutions of LPS, IFN-γ and Ebselen 
were prepared as follows: 
LPS (Sigma) stock was 1000 µg/ml in 10 mg/ml bovine serum albumin solution 
(BSA, prepared in PBS). It is not recommended to store LPS in stock solutions 
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with concentrations lower than 1000 µg/ml. Stock solutions were stored at -80oC 
and each tube went through the thaw-refreeze cycle no more than twice. Stock 
solution was spun at high speed (≥10,000 x g) for 2 minutes following thawing.  
 
Mouse IFN-γ (BD Biosciences) stock was 25 µg/ml in 10 mg/ml BSA solution. 
Storage and centrifugation conditions are the same as for LPS stock.  
 
Ebselen (Sigma) solution was 50 mM in 1:1 DMSO:ethanol. The stock was 
stored at 4oC. It is worth noting that the Ebselen solution can undergo light- and 
air-induced oxidation, which reduces the shelf life of the stock solution. 
Therefore, it may be necessary to monitor the decline of the antioxdiant property 
of Ebselen and use prepare fresh stocks periodically. 
 
 
Cell Culture— RAW264.7 cells were obtained from the American Type Culture 
Collection and were maintained in Dulbecco’s modified Eagle’s medium 
(Invitrogen, Carlsbad, CA) containing 10% (v/v) fetal bovine serum and 100 
units/ml penicillin and streptomycin (Invitrogen) in 5% CO2 at 37°C. Primary 
macrophages from C57BL/6J mice were isolated by peritoneal lavage 72 h 
following intraperitoneal injection with 2 ml of thioglycolate medium. ATP7A-
depleted RAW264.7 cells (ATP7A-RNAi) were generated by stable transfection 
of a pRS vector harboring a 29 nucleotide short hairpin RNA against ATP7A 
(Origene, Rockville, MD) and selected in 25 µg/ml puromycin (Invitrogen).  
Control cells were transfected with the same vector expressing shRNA against 
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GFP (Origene). Lipofectamine 2000 (Invitrogen) was used for all transfections.  
Copper Uptake Studies— Radioactive copper (64Cu) was purchased from the 
Mallinckrodt Institute of Radiology, Washington University (Saint Louis, MO). 
64Cu uptake was assayed as described previously (93).  RAW264.7 macrophage 
cells were grown in triplicate 6 well trays and cultured overnight in serum-free 
medium in the presence or absence of 25 ng/ml IFN-γ (BD Biosciences, Franklin 
Lakes, NJ).  Cells were washed with serum-free DMEM medium and then 
exposed to 1 µM 64Cu for 5 min, washed extensively in ice-cold PBS and 
radioactivity was measured using a gamma counter.  Counts were normalized 
against total protein. 
 
 
Bacterial Survival Assay— RAW264.7, control-RNAi or ATP7A-RNAi 
macrophage cells were activated by overnight treatment in serum-free DMEM 
medium with or without 25 ng/ml IFN-γ. Where indicated, either 20 µM CuCl2 or 
50 µM Ebselen was also added to the cells. Macrophages were then detached by 
scraping into ice-cold serum-free media, washed twice, and resuspended in 
triplicate in serum-free medium at a concentration of 4 x 106 cells/ml. E. coli wild-
type strain W3110 and the copA knockout strain DW3110 (367, 368) were grown 
to stationary phase and mixed with macrophages at a macrophage:bacteria ratio 
of 1:10 or 1:1. Bacterial phagocytosis was allowed to proceed for 30 min at 37oC 
and extracellular bacteria removed by two washes with phosphate buffered 
saline containing 12.5 µg/ml Gentamicin (Gibco). One set of samples (uptake 
group) was lysed in 0.1% (v/v) Triton X-100 solution and plated onto LB-agar 
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plates for counting to provide bacterial uptake values.  The remaining set (kill 
group) was incubated for 1-2 hours as indicated at 37oC in serum-free media to 
allow bacterial killing to occur, lysed, and then plated onto LB-agar. Colony 
numbers were normalized against the total protein content of each sample and 
bacterial survival was determined by dividing the number of colonies in the killing 
group by those in the uptake group.  
 
 
In vitro bacterial ROS survival assay This protocol is based on previously 
published methods (369). Wild-type E. coli W3110 was grown overnight to 
stationary phase. The next day, 1 ml of bacterial solution was diluted into 4 ml LB 
and grown for 2-3 hours to exponential phase (OD600 = 0.2 - 0.3). The bacterial 
solution was then pelleted and the LB discarded.  
The bacterial pellet was washed twice with PBS + 67 µM EDTA followed by one 
wash with PBS only. The bacterial pellet was then re-suspended in buffer 
containing 0.1M sodium phosphate pH 7.4, and 0.15 M sodium chloride in water. 
The bacterial suspension was then aliquoted into 1 ml samples. Samples were 
run in triplicates. The sample treatments were as follows: 
- Buffer only (designated as untreated group in results section) 
- Buffer + 500 µM ascorbic acid 
- Buffer + 500 µM ascorbic acid + 10 µM CuCl2 (copper group) 
- Buffer + 500 µM ascorbic acid + 500 µM H2O2 (H2O2 group) 
- Buffer + 500 µM ascorbic acid + 10 µM CuCl2 + 500 µM H2O2 (H2O2 + copper 
group) 
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- Buffer + 10 µM CuCl2 
- Buffer + 500 µM H2O2 
The treatments were added to the bacterial solutions in the following order: 1) 
ascorbic acid, 2) copper, 3) H2O2. The samples were incubated at 37oC for 20 
min. A 1/1000 dilution of each sample was plated on LB + ampicillin and bacterial 
survival rates were calculated and expressed as percentage survival compared 
to the untreated group. 
 
 
Immunofluorescence Microscopy— RAW264.7 cells or primary peritoneal 
macrophages were grown overnight on sterile glass coverslips in serum-free 
media. The next day, all treatment groups received a change of serum-free 
media, and where indicated, were treated with 100 ng/ml LPS, 25 ng/ml IFN-γ, or 
20 µM CuCl2, in the presence or absence of 50 µM Ebselen for 24 hours. Cells 
were then washed in ice-cold PBS, fixed in 4% (w/v) paraformaldehyde, 
permeabilized in 0.05% Triton X-100, and blocked overnight in 1% (w/v) casein 
solution. Cells were then incubated for 1 hour in the presence of primary 
antibodies against the C-terminal portion of ATP7A, and against mouse GM130. 
This was followed by three 10-minute washes in PBS, and a 1-hour incubation 
with the following secondary antibodies: anti-rabbit IgG conjugated to Alexa-488 
(green) and anti-mouse IgG conjugated to Alexa-594 (red) (Molecular Probes). 
Cells received 2 washes in PBS followed by a 15-minute incubation in PBS 
containing the nuclear stain 4',6-diamidino-2-phenylindole (DAPI, 1:12,500 
dilution), and another wash in PBS. Cells were then given a long wash in PBS 
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overnight at 4oC. The next day, slides were mounted on glass plates using the 
mounting medium Mowiol and allowed to dry before microscopy.  
 
 
Immunoblot Analysis—Cells cultured in 6-well trays were scraped into ice-cold 
phosphate-buffered saline (PBS) and pelleted by centrifugation. After several 
washes in ice-cold PBS, the cells were lysed by one of two methods: 1) for 
ATP7A protein detection, cells were lysed by sonication in lysis buffer containing 
62.5 mM Tris-Cl, pH 6.8, 2% (w/v) SDS, 1 mM EDTA, and protease inhibitor mix 
(Roche Applied Science) 2) for CTR1 protein detection, cells were lysed on ice 
for 20 min in lysis buffer containing 62.5 mM Tris-Cl, pH 6.8, 1% (v/v) Triton X-
100, 0.1% (w/v) SDS, 1 mM EDTA, and protease inhibitor mix. Samples were 
centrifuged for 10 min at 16,000 x g, and the protein concentration of the lysates 
was determined using a DC protein assay kit (Bio-Rad). Twenty µg of protein 
lysates were resuspended in loading buffer containing 100 mM dithiothreitol, 
separated using SDS-PAGE, transferred to nitrocellulose membranes, and 
detected by chemiluminescence (370). As a loading control, the same 
membranes were stripped and re-probed with mouse anti-tubulin antibody. For 
the detection of secreted ceruloplasmin, conditioned media were collected and 
concentrated (Amicon Ultra). The corresponding sample lysates were used to 
measure protein content and adjust sample loading and to probe for tubulin as a 
loading control.  
The antibody dilutions in 1% (w/v) casein solution and incubation times were as 
follows: 1) for detection of ATP7A protein, an antibody against the C-terminal end 
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of the protein was raised by our laboratory and named MNK.  Membranes were 
probed with a 1:5,000 dilution of this antibody for 2 hours at room temperature, 2) 
for detection of CTR1 protein the anti-Ctr1 antibody (a gift of Dennis Thiele, Duke 
University) was used at 1:500 dilution overnight at room temperature, or 3) the 
sheep anti-ceruloplasmin antibody (Abcam) was used at 1:250 dilution overnight 
at 4oC. Western blot bands were quantified using the Quantity One software 
(Biorad). Each band expression was normalized against its own tubulin control, 
and expression is expressed as relative to the untreated control.  
 
 
Latex Bead Phagocytosis and Phagosome Purification— RAW264.7 cells were 
activated by overnight treatment with 25 ng/ml IFN-γ and exposed to a 1/200 
dilution of 3 µm latex beads (Sigma) for 90 min at 37oC to allow phagocytosis to 
proceed.  Cells were then washed with PBS to remove extracellular beads and 
fixed in paraformaldehyde and processed for immunofluorescence, as above.  In 
other experiments, phagosomes were purified by sucrose gradient centrifugation, 
as previously described (371). 
 
 
Ceruloplasmin Activity— Conditioned media was used to assess ceruloplasmin 
activity. The media was concentrated using Amicon Ultra-4 filter tubes (Millipore) 
and ceruloplasmin’s p-phenylenediamine oxidase activity was assessed, as 
previously described (372). Ceruloplasmin activity values were normalized 
against total cell protein content. It is to be noted here that serum-containing 
media should be used for the successful detection of ceruloplasmin activity.  
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2.4 Results 
 
 
 
Copper enhances the bactericidal activity of macrophages— We began this 
study by determining the impact of copper supplementation on the bactericidal 
activity of the murine macrophage cell line, RAW264.7. The cells were treated 
overnight with the pro-inflammatory cytokine interferon-gamma (IFN-γ) in the 
presence or absence of 20 µM copper added to the medium, and their ability to 
kill E. coli was determined the following day. Bacterial survival was significantly 
reduced in copper-treated RAW264.7 macrophages relative to control cells (Fig. 
2.1A), suggesting that copper potentiated the bactericidal activity of these cells. 
One suggested mechanism for copper-mediated bacterial killing is through 
Fenton chemistry. The oxidative burst that follows bacterial phagocytosis by 
macrophages leads to the rapid production of hydrogen peroxide (H2O2), which 
can interact with intracellular copper to produce the highly reactive and toxic 
hydroxyl radical (OH•) (2-4). Indeed, the potentiation of bactericidal activity by 
copper was prevented by the antioxidant, Ebselen, (Fig. 2.1B), suggesting that it 
was dependent on reactive oxygen species (ROS). Copper or Ebselen 
treatments did not alter the phagocytosis of E. coli compared to control 
RAW264.7 cells (data not shown). Furthermore, in vitro exposure of E. coli to 
hydrogen peroxide (H2O2) in the presence of copper significantly reduced the 
rate of bacterial survival compared to H2O2 or copper alone (Fig. 2.1C).  These 
findings suggest that copper can promote the bactericidal activity of RAW264.7 
macrophages in a ROS-dependent manner.    
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FIGURE 2.1. Copper enhances bacterial killing by RAW264.7 macrophage 
cells. A, RAW264.7 macrophages were treated with IFN-γ in the presence of 
absence of 20 µM copper prior to exposure to E. coli for 30 min to allow 
phagocytosis to occur. After removal of extracellular bacteria, bacterial survival 
was measured after incubations for 1 h and 2 h at 37oC and expressed as a 
percentage of initial internalized E. coli (mean ± SD; n = 3; p<0.05). B, Bacterial 
survival was assayed in IFN-γ-treated RAW264.7 macrophages in the presence 
or absence of 20 µM copper and 50 µM Ebselen (mean ± SD; n = 3; p<0.05). C, 
Bacterial survival was assessed following exposure of E. coli to 500 µM H2O2, 10 
µM CuCl2 or H2O2 and CuCl2 combined in the presence of 500 µM ascorbic acid 
(mean ± SD; n = 3; p<0.05). Different letters signify values of significant 
difference. 
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Fig. 2.1 
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Inflammatory mediators induce the expression of CTR1 and ATP7A copper 
transporters— Since copper potentiated the bacteridical activity of RAW264.7 
cells, we investigated whether copper homeostasis might be altered in these 
cells following stimulation with pro-inflammatory agents. Treatment with IFN-γ 
was found to stimulate copper uptake activity in RAW264.7 cells (Fig. 2.2A) and 
immunoblot analysis revealed an increase in the expression of the copper 
importer, CTR1 (Fig. 2.3A). CTR1 expression was also induced in RAW264.7 
cells exposed to lipopolysaccharide (LPS), a bacterial cell wall component (Fig. 
2.3B). LPS and IFN-γ also stimulated CTR1 expression in primary macrophages 
isolated from the peritoneum of mice (Fig. 2.3C). These findings suggest that the 
inflammatory response of macrophages stimulates CTR1-mediated copper 
uptake. Consistent with this hypothesis, the total cellular copper concentrations 
were elevated in LPS- and IFN-γ-treated RAW264.7 cells (Fig. 2.2B). Further 
evidence of elevated intracellular copper content was the finding of reduced 
expression of CCS in IFN-γ-treated RAW264.7 cells, a protein that is known to be 
proteolytically degraded in response to elevated levels of copper (185) (Fig. 
2.2C). We then investigated the effect of pro-inflammatory agents on another 
copper transporter, ATP7A. The ATP7A protein is a copper transporting P-type 
ATPase responsible for delivering copper from the cytoplasm into secretory 
compartments and is located in the trans-Golgi network. ATP7A protein 
expression was increased in response to IFN-γ and LPS in RAW264.7 cells 
(Figs. 2.4A and 2.4B) and in primary peritoneal macrophages (Fig. 2.4C). 
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FIGURE 2.2. IFN-γ  alters copper homeostasis in RAW264.7 macrophages.  
A, Copper uptake activity. RAW264.7 cells were pre-treated with serum-free 
media ± 25 ng/ml IFN-γ for 24 hours and copper uptake in the presence of 1 µM 
64Cu was measured over 5 min and normalized against total protein (mean ± SD; 
n = 3). B, Atomic absorption spectrometry (AAS) analysis of total copper content 
of RAW264.7 cells treated with serum-free media, 100 ng/ml LPS or 25 ng/ml  
IFN-γ for 24 h. Values for copper content were normalized against total protein 
content of cell lysates (mean ± SD; n = 3). C, Western blot analysis of CCS 
protein expression in RAW264.7 macrophage cells exposed to 100 ng/ml LPS or 
25 ng/ml IFN-γ. Tubulin was detected as a loading control.  
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Fig. 2.2 
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FIGURE 2.3. Inflammatory mediators increase the expression of CTR1 in 
RAW264.7 and primary peritoneal macrophages. Western blot analysis of 
CTR1 protein expression in: A, RAW264.7 macrophage cells exposed to a range 
of IFN-γ concentrations; B, RAW264.7 macrophage cells exposed to a range of 
LPS concentrations; C, Primary peritoneal murine macrophages cultured in 
serum-free media ± 100 ng/ml LPS or 25 ng/ml IFN-γ. Tubulin was detected as a 
loading control. The numbers shown under the immunoblot bands represent 
relative expression, as calculated using Quantity One software (Biorad). The 
expression level of each sample was first normalized against its own tubulin 
control. BSF (Basal serum-free media). 
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Fig. 2.3 
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FIGURE 2.4. inflammatory mediators increase the expression of ATP7A in 
RAW264.7 and primary peritoneal macrophages. Western blot analysis of 
ATP7A protein expression in: A, RAW264.7 macrophage cells exposed to a 
range of IFN-γ concentrations; B, RAW264.7 macrophage cells exposed to a 
range of LPS concentrations; C, Primary peritoneal murine macrophages 
cultured in serum-free media ± 100 ng/ml LPS or 25 ng/ml IFN-γ. Tubulin was 
detected as a loading control. The numbers shown under the immunoblot bands 
represent relative expression, as calculated using Quantity One software 
(Biorad). The expression level of each sample was first normalized against its 
own tubulin control. 
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Fig. 2.4 
 
 76 
Another noteworthy finding is that both LPS and IFN-γ induced an increase in 
mRNA levels of the CTR1 and ATP7A transporters (Fig. 2.5). It is unknown 
whether this increase in mRNA levels is due to transcriptional or post-
transcriptional regulation. Further studies are needed to elucidate the underlying 
mechanisms. Together, these results suggest that the stimulation of 
macrophages by inflammatory agents promotes copper uptake and increased 
expression of CTR1 and ATP7A proteins. 
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FIGURE 2.5. Inflammatory mediators increase the expression levels of 
CTR1 and ATP7A mRNA. RAW264.7 cells were grown in serum-free media ± 
100 ng/ml LPS or 25 ng/ml IFN-γ for 0, 2, 6, 12 or 28 hours. RNA was purified 
and mRNA expression of CTR1 (A) and ATP7A (B) was quantified by real-time 
PCR. CTR1 and ATP7A mRNA levels were normalized against GAPDH. Fold 
expression is relative to a basal treatment at each time point (mean ± SD; n = 3).  
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Fig. 2.5 
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IFN-γ and LPS stimulate copper-dependent ATP7A trafficking to post-Golgi 
vesicles that overlap with the phagosome— Previous studies have demonstrated 
that elevated intracellular copper levels stimulate the trafficking of the ATP7A 
protein from the trans-Golgi network to post-Golgi vesicles in a variety of cell 
types (16-19). Based on these findings, we hypothesized that ATP7A trafficking 
might also be stimulated by the increased uptake and accumulation of copper in 
RAW264.7 cells treated with IFN-γ or LPS. Immunofluorescence microscopy was 
used to localize the ATP7A protein in the perinuclear region of RAW264.7 
macrophages, consistent with its location in the trans-Golgi network (Fig. 2.6A, 
upper panel). As expected, the addition of copper to the culture medium 
stimulated the trafficking of ATP7A to post-Golgi vesicles (Fig. 2.6A, upper 
panel). Interestingly, when RAW264.7 cells were exposed to IFN-γ or LPS 
without copper supplementation, the ATP7A protein was also distributed to post-
Golgi vesicles (Fig. 2.6A, upper panel). IFN-γ and LPS did not alter the location of 
the Golgi matrix marker protein GM130, suggesting that the shift in ATP7A 
distribution was not a result of a general Golgi disruption (Fig. 2.6A, lower panel).  
ATP7A trafficking was also observed in primary peritoneal macrophages in 
response to LPS and IFN-γ stimulation (Fig. 2.6B). Since the trafficking of ATP7A 
is known to be responsive to copper, we examined whether these effects of IFN-γ 
could be inhibited using the membrane permeable copper chelator, 
tetrathiomolybdate (TTM). Treatment of RAW264.7 cells with TTM suppressed 
the trafficking of ATP7A in response to IFN-γ consistent with a role for copper in 
this process (Fig. 2.7A). Interestingly, Western blot analysis indicated that the 
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increased levels of ATP7A in response to either IFN-γ or LPS were not blocked 
by TTM (Fig 2.7B). Taken together, these findings suggest that IFN-γ stimulates 
ATP7A trafficking in a copper-dependent manner that is different from the 
copper-independent mechanism by which it stimulates ATP7A expression.  
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FIGURE 2.6. Inflammatory mediators stimulate trafficking of the ATP7A 
protein in RAW264.7 and primary peritoneal macrophage cells. A, 
Immunofluorescence analysis of ATP7A protein in RAW264.7 cells grown for 24 
h in the presence or absence of 100 ng/ml LPS, 25 ng/ml IFN-γ, or 20 µM CuCl2. 
Cells were fixed, permeabilized and probed with antibodies against ATP7A and 
anti-rabbit antibodies conjugated to Alexa-488 (green; upper panel) or antibodies 
against GM130 and anti-mouse IgG antibodies conjugated to Alexa-594 (red; 
lower panel). Nuclei were labeled with DAPI (blue). B, ATP7A traffics in response 
to LPS and IFN-γ in thioglycollate-elicited primary peritoneal macrophages 
derived from C57BL/6 mice.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
Fig. 2.6 
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FIGURE 2.7. The IFN-γ-stimulated trafficking of ATP7A is mediated by 
copper. A, IFN-γ-induced trafficking of ATP7A is inhibited by the copper chelator 
tetrathiomolybdate (TTM). RAW264.7 macrophage cells were cultured in the 
presence of IFN-γ ± 10 nM TTM. Cells were fixed, permeabilized and probed with 
antibodies against for ATP7A and anti-rabbit IgG antibodies conjugated to Alexa-
488 (green). Nuclei were labeled with DAPI (blue). B, the copper chelator TTM 
does not inhibit the increase in ATP7A protein expression in response to IFN-γ. 
RAW264.7 cells were treated with serum-free media or 25 ng/ml IFN-γ in the 
presence or absence of 10 nM TTM. ATP7A protein was detected by Western 
blot analysis. Tubulin was detected as a loading control. The numbers shown 
under the immunoblot bands represent relative expression, as calculated using 
Quantity One software (Biorad). The expression level of each sample was first 
normalized against its own tubulin control. 
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Fig. 2.7 
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We then examined whether IFN-γ stimulates the trafficking of ATP7A to a 
vesicular population that overlaps with the phagosomal compartment in 
RAW264.7 cells. Phagocytosis of latex beads by IFN-γ-stimulated RAW264.7 
cells was used to label the phagosomal compartment, and the intracellular 
location of ATP7A was then examined in the same cells using 
immunofluorescence microscopy. As shown in Figure 2.8, ATP7A was partially 
distributed to compartments that also phagocytosed latex beads seen in the 
bright field panel (Fig. 2.8A). In separate experiments, the subcellular 
phagosomal membrane compartment containing the internalized latex beads was 
isolated from RAW264.7 cells. Western blot analysis of these preparations 
demonstrated a marked enrichment of the LAMP-1 protein, a phagosomal 
marker, relative to total cell lysate (Fig. 2.8B). Significantly, the ATP7A protein 
was also abundant in the phagosomal fraction, which lacked a marker of the 
Golgi matrix, GM130. Taken together, these studies suggest that pro-
inflammatory stimuli cause the increased flux of copper to the ATP7A protein and 
its partial redistribution to phagosomal compartments.  
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FIGURE 2.8. IFN-γ  induces the redistribution of ATP7A into the phagosomal 
compartment of RAW264.7 macrophage cells. A, Partial co-localization of 
ATP7A with phagocytosed latex beads. RAW264.7 macrophages were 
stimulated overnight with IFN-γ and allowed to phagocytose latex beads. After 
fixing cells, ATP7A was detected as described above. The bright field panel 
shows phagocytosed beads with the adjacent panel and inset showing the 
localization of ATP7A (α-MNK). B, Co-fractionation of ATP7A with the 
phagosome. The phagosomal compartment was isolated via subcellular 
fractionation of membranes containing the internalized latex beads from 
RAW264.7 cells. This fraction (Beads) was subjected to SDS-PAGE as well as 
the total protein fraction (Total). Immunoblot analysis revealed abundant ATP7A 
in the Lamp-1 positive bead fraction, which lacked the Golgi marker protein 
GM130.  Note that Lamp-1 was poorly detected in total lysates. 
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Fig. 2.8 
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ATP7A-dependent copper transport is required for bactericidal activity of 
RAW264.7 macrophages— The above findings highlight the possibility that 
ATP7A-dependent copper transport into the phagosome is important for 
macrophage microbiocidal activity. To test this hypothesis, we investigated the 
effect of RNAi-mediated depletion of ATP7A expression on bacterial killing by 
RAW264.7 cells. RAW264.7 cells were stably transfected with a construct 
harboring a 29-nucleotide short hairpin against ATP7A (ATP7A-RNAi). This 
resulted in robust silencing of ATP7A gene expression in the ATP7A-RNAi cells, 
relative to control cells transfected with an irrelevant RNAi against GFP (Fig. 
2.9A). ATP7A gene silencing did not prevent the upregulation of the inducible 
nitric oxide synthase (iNOS) associated with IFN-γ (373) (Fig. 2.9B). However, 
the activation of secreted ceruloplasmin induced by IFN-γ was suppressed in the 
ATP7A-RNAi cells compared to the control cells (Fig. 2.9D), whereas secreted 
ceruloplasmin protein levels were not affected by ATP7A gene silencing (Fig. 
2.9C). This suggests that, while copper delivery to the secretory pathway is 
deficient in the ATP7A-RNAi cells, thereby suppressing the activity of copper-
dependent enzymes such as ceruloplasmin, non copper-dependent pathways 
are not affected in this cell line. Significantly, ATP7A silencing reduced the 
bactericidal activity of RAW264.7 cells, as evidenced by the higher bacterial 
survival in ATP7A-RNAi cells relative to control cells (Fig. 2.10A). Moreover, the 
addition of copper to ATP7A-RNAi cells bypassed this reduction in bactericidal 
activity (Fig. 2.10A). These findings support the hypothesis that ATP7A-
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dependent copper transport into the phagosome is important in bactericidal 
activity of macrophages.   
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FIGURE 2.9. ATP7A gene silencing by siRNA suppresses copper delivery to 
ceruloplasmin but does not alter iNOS expression during inflammation.  
A, RNAi-mediated silencing of the ATP7A protein. Western blot analysis of 
ATP7A protein levels in RAW264.7 cells stably transfected with either ATP7A-
RNAi or control-RNAi against GFP. B, ATP7A-RNAi does not suppress the IFN-γ-
induced upregulation of iNOS protein expression. Western blot analysis of iNOS 
protein expression in control-RNAi and ATP7A-RNAi cells treated with 25 ng/ml 
IFN-γ for 24 hours. C, ATP7A-RNAi does not suppress the increase in secreted 
ceruloplasmin protein associated with IFN-γ treatment of RAW264.7 
macrophages. Western blot analysis of ceruloplasmin protein in conditioned 
media from control-RNAi and ATP7A-RNAi cells treated with 25 ng/ml IFN-γ for 
24 h. D, ATP7A-RNAi suppresses the increase in secreted ceruloplasmin activity 
associated with IFN-γ treatment of macrophages. Ceruloplasmin activity from 
concentrated conditioned media from control-RNAi and ATP7A-RNAi 
macrophages exposed to IFN-γ   ± 2 µM CuCl2 was assessed. Values for 
ceruloplasmin activity were normalized against total protein content of each 
sample (mean ± SD; n = 3; p<0.05). The numbers shown under the immunoblot 
bands represent relative expression, as calculated using Quantity One software 
(Biorad). The expression level of each sample was first normalized against its 
own tubulin control. 
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Fig. 2.9 
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We further explored this hypothesis by testing whether the ability of E. coli to 
export copper would influence its susceptibility to killing by RAW264.7 
macrophages. The CopA protein is a copper exporting P-type ATPase in E. coli 
similar to the ATP7A protein of mammals, and the ∆copA mutant is 
hypersensitive to elevated copper concentrations (20). Interestingly, the ∆copA 
mutant was more susceptible to killing by RAW264.7 macrophages compared to 
its parental wild type E. coli strain (Fig. 2.10B). Moreover, the survival of the 
∆copA strain was increased within the ATP7A-RNAi cells relative to control cells 
(Fig. 2.10C), indicating that the increased susceptibility of the ∆copA mutant was 
dependent on the level of ATP7A expression within its macrophage host. In 
addition, in vitro exposure to a H2O2 and copper cocktail significantly reduced the 
survival of the ΔcopA mutant bacteria compared to wild type, suggesting that the 
increased copper sensitivity of the ΔcopA mutant may be ROS-mediated (Fig. 
2.10D). These data suggest that copper homeostasis within both bacteria and 
macrophages is a determinant of bacterial survival, and identify copper as an 
unexpected nexus of host pathogen interactions.  
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FIGURE 2.10. Bactericidal activity of RAW264.7 macrophages is dependent 
on ATP7A-mediated copper transport. Control-RNAi and ATP7A-RNAi 
macrophage cells stimulated with IFN-γ were compared in their bactericidal 
activity against W3110 E. coli or WD3110 E. coli harboring a deletion of the copA 
gene. A, Percent survival of W3110 E. coli in control-RNAi or ATP7A-RNAi 
macrophages stimulated with IFN-γ ± 20 µM CuCl2. The rate of bacterial survival 
was significantly increased in ATP7A-RNAi compared to control-RNAi 
macrophages. The presence of copper significantly reduced bacterial survival in 
both RNAi cell lines  (mean ± SD; n = 3; p<0.05). B, The survival of W3110 E. 
coli in RAW264.7 macrophages was compared to that of the copA knockout 
WD3110 E. coli. Percent survival data is shown for 1 and 2 h kill times (post-
uptake) (mean + SD; n = 3; p<0.05). C, The susceptibility of WD3110 E. coli is 
attenuated in the absence of ATP7A. Percent survival of WD3110 E. coli was 
significantly increased in ATP7A-RNAi macrophages compared to control-RNAi 
macrophages (mean ± SD; n = 3; p<0.05). D) Bacterial survival of W3110 E. coli 
and WD3110 (ΔCopA) E. coli was assessed following exposure of E. coli to 500 
µM H2O2 and 10 µM CuCl2 combined in the presence of 500 µM ascorbic acid. 
Bacterial survival rates were calculated and expressed as percentage survival 
compared to the untreated group (mean ± SD; n = 3; p<0.05). 
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Fig. 2.10 
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2.5 Discussion 
 
 
 
Copper is an essential nutrient. Its deficiency has been linked to disorders such 
as anemia, neurodegenerative and cardiovascular defects and other illnesses 
(1). Inadequate copper nutrition in human patients is often associated with a 
decrease in the number of circulating white blood cells or neutropenia (281-284). 
Copper deficiency in macrophage cells results in their inability to adequately fight 
pathogens. Not only is copper essential for the function of the immune system, 
but inflammatory conditions and infections raise the body’s physiological need for 
copper, as illustrated by the associated rise in serum copper levels in human 
patients (265-272, 360, 362). Furthermore, copper has long been recognized as 
a biocidal agent (374).  
 
In this study, we find evidence that the biocidal property of copper has been 
harnessed by cells of the immune system to kill bacteria. We demonstrate for the 
first time that specific changes in macrophage copper homeostasis occur in 
response to inflammatory stimuli, and promote copper-dependent bacterial 
killing. Under inflammatory conditions, macrophage cells increase both uptake 
and retention of copper. We observe an increase in CTR1 protein levels in both 
the RAW264.7 murine macrophage cell line and primary peritoneal murine 
macrophages in response to the pro-inflammatory agents IFN-γ and LPS. This 
increase in CTR1 protein expression is associated with increased 64Cu uptake by 
macrophage cells, as well as increased total copper content during inflammation. 
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Interestingly, inflammation also results in an increased expression of ATP7A 
protein, along with a copper-dependent relocalization of ATP7A from the TGN 
into a vesicular compartment. This trafficking process is dependent on increased 
flux of copper to the ATP7A protein, since it is blocked by copper chelation by 
TTM. Our finding of elevated expression of the CTR1 copper importer and 
increased copper uptake activity in response to IFN-γ, suggests that this pathway 
is a likely source of copper for ATP7A. Additionally, the accumulation of copper 
within activated macrophages suggests that the trafficking of ATP7A is 
associated with redistribution of copper into intracellular compartments rather 
than copper export.  
 
We hypothesized that one such compartment could be the phagosome. Previous 
studies using x-ray microprobe analysis have demonstrated that copper levels 
within the phagosome increase 10-fold to approximately 180 µM in IFN-γ-
stimulated macrophages exposed to Mycobacterium avium (285). However, no 
known copper transporter associated with the phagosome has been identified. 
Exactly how copper finds its way into the phagosomal compartment during 
inflammatory conditions was unknown. We hypothesized that the trafficking of 
ATP7A associated with inflammation would serve to partially redistribute 
intracellular copper into the phagosome, where there is an increased need for 
copper. Indeed, our studies show that ATP7A-rich vesicles partially overlap with 
the phagosomal compartment, as revealed by immunofluorescence microscopy 
and subcellular fractionation.   
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Our most significant finding sheds light on the role of ATP7A in bacterial killing by 
macrophages. Consistent with the observed pattern of ATP7A trafficking, we 
show that macrophage-mediated bacterial killing is dependent on the expression 
of the ATP7A copper transporter, as evidenced by the attenuated bactericidal 
activity when ATP7A is silenced. These findings suggest that copper transport 
into the phagosome via the ATP7A protein is a novel determinant of bacterial 
killing by macrophages.  
 
The role of copper in bacterial killing has been attributed to its property as a 
transition metal and its ability to participate in Fenton reactions. During the 
oxidative burst associated with bacterial phagocytosis, superoxide production 
increases dramatically within the phagosomal compartment. Hydrogen peroxide 
is generated spontaneously from superoxide created by the respiratory burst; 
however, hydrogen peroxide is only lethal at supraphysiological millimolar 
concentrations that are several orders of magnitude greater than those found 
within activated leukocytes (375). On the other hand, studies have shown that 
physiological concentrations of hydrogen peroxide plus cuprous ions are lethal to 
E. coli (369), presumably owing to the formation of the OH• radical, the most toxic 
of all reactive oxygen species (257, 289). Copper enrichment of the phagosome 
is thus important in providing the transition metal catalyst required for OH• radical 
production during the oxidative burst. We propose that a lethal cocktail of copper 
and hydrogen peroxide may be the underlying mechanism by which ATP7A-
dependent copper transport into the phagosome promotes bacterial killing. Such 
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a model is consistent with our finding that the combination of H2O2 and copper is 
significantly more effective at killing E. coli in vitro compared to H2O2 or copper 
alone. Furthermore, the enhanced bactericidal activity in copper-treated 
RAW264.7 macrophages is attenuated by the antioxidant Ebselen, a mimic of 
glutathione peroxidase that reduces the levels of intracellular H2O2 (376-379), 
suggesting a requirement for reactive oxygen species.  The increased acquisition 
of copper by the phagocytic compartment of the macrophage host cells is 
accompanied by a compensatory increase in copper efflux in the ingested 
bacteria. Indeed, a notable finding of our study is that the copper-sensitive ΔcopA 
mutant of E. coli is more susceptible to macrophage-mediated killing than the 
wild type strain. Since the CopA protein functions in the export of cytoplasmic 
copper across the plasma membrane (380), these findings suggest that copper 
export is a bacterial defense mechanism against macrophage-mediated killing. 
Consistent with this hypothesis, the susceptibility of the ΔcopA mutant to killing is 
reduced by depletion of ATP7A in the macrophage host. These intriguing findings 
argue that copper transport by both host and pathogen is a unique and mutually 
opposing tactic in the struggle for supremacy; i.e., ATP7A-mediated copper 
transport into the phagosome is countered by copper export by the bacterium 
(Fig. 2.11). This concept of copper export as a defense strategy is not unique to 
E. coli. Indeed, the virulence of Pseudomonas aeruginosa in mice is severely 
decreased (20-fold) by mutations in the bacterial copper exporter, CueA (286). 
Additionally, the expression of several metal ion exporters including two putative 
copper efflux transporters, CopA1 and CopA2, are induced in Legionella 
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pneumophila upon phagocytosis by macrophages (288). Moreover, plasmids that 
increase the virulence of Klebsiella pneumoniae and Shigella sonnei harbor 
putative copper resistance genes (381, 382).  
 
Changes in the serum concentrations of micronutrients following infection are 
characteristic of the acute phase inflammatory response. Serum levels of iron, 
zinc, selenium, retinol, riboflavin, and pyridoxine are all reported to decrease 
following inflammatory insult (262). The proposed physiological rationale for 
these changes is nutrient deprivation that would serve to limit proliferation of the 
invading microbe (262). A well-documented example is the contest between host 
and pathogen over limiting iron stores, which plays a critical role in determining 
the outcome of infection (261, 262). In contrast to the above micronutrients, 
systemic copper concentrations are widely reported to increase in response to 
acute and chronic inflammation (263-274, 360-364). While the secreted copper-
containing protein, ceruloplasmin, is partially responsible for this rise in serum 
copper (120), the non-protein bound fraction of copper in the serum is also 
increased during inflammation (263). Moreover, radiotracer studies with 64Cu 
have demonstrated that copper accumulates at sites of inflammation (275), and 
within the exudates of wounds and burns relative to serum (276, 277). Although 
the physiological rationale of these systemic increases in copper concentration 
are unclear, our findings point to the possibility that such changes may provide 
localized reserves of copper for macrophage-mediated bactericidal activity.   
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FIGURE 2.11. Model of copper-mediated bacterial killing by macrophages.  
Stimulation of macrophage cells by inflammatory signals or bacterial particles 
induces copper uptake via increased expression of the copper importer CTR1. 
The increase in intracellular copper content induces the trafficking of the copper 
exporter ATP7A into post-Golgi vesicles that partially overlap with the 
phagosomal compartment. Together with the increased expression of ATP7A 
protein, the trafficking of ATP7A to the phagosome drives copper transport into 
this compartment, where copper contributes to bacterial killing via Fenton 
chemistry and production of the hydroxyl radical (OH•). The attack on the 
bacteria in the phagosomal compartment induces copper export as a pathogen 
defense mechanism. 
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Fig. 2.11 
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CHAPTER 3 
 
 
OXYGEN IS A NOVEL REGULATOR OF COPPER METABOLISM 
IN MACROPHAGES 
 
 
3.1 Summary 
 
 
 
 Copper is an essential cofactor of enzymes involved in a variety of important 
metabolic processes including ATP production, iron transport, and antioxidant 
defense. The maintenance of copper homeostasis requires a balance of copper 
uptake and export, as well as the appropriate partitioning of copper between the 
cytoplasm, mitochondria and secretory compartments. Although many of the 
proteins involved in copper homeostasis have been identified, it is unknown 
whether specific pathophysiological conditions lead to compensatory changes in 
the intracellular copper distribution. In this study, we identify striking alterations in 
copper homeostasis in response to hypoxia in RAW264.7 macrophage cells. 
Hypoxia induced the expression of the copper importer, CTR1, resulting in 
increased copper uptake. However, the activities of cuproenzymes superoxide 
dismutase and cytochrome c oxidase were inhibited by hypoxia. Significantly, 
copper delivery into secretory compartments via the ATP7A copper transporter 
was increased as evidenced by the enhanced activity of the ferroxidase 
ceruloplasmin, and trafficking of ATP7A to post-Golgi compartments in hypoxic 
macrophages in vitro and in vivo. The trafficking of ATP7A was dependent on 
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mitochondria-generated reactive oxygen species in hypoxic macrophages, 
suggesting that this process is mediated by oxidative stress. Collectively, these 
findings demonstrate that hypoxia alters the intracellular copper hierarchy in 
macrophages to favor copper delivery to the secretory pathway, and underscores 
the potential for other pathophysiological conditions to regulate adaptive 
responses involving altered copper distribution to cuproenzymes. 
 
 
 3.2 Introduction 
 
 
 
Copper is a trace element that is critical for aerobic life. Its ability to accept and 
donate electrons has been harnessed by a select group of enzymes that function 
in mitochondrial respiration, connective tissue formation, pigmentation, iron 
oxidation, neurotransmitter processing, and antioxidant defense (110, 114, 383). 
However, this same redox property of copper and its ability to generate reactive 
oxygen species, also underscores its potential toxicity. For this reason, copper-
handling pathways have evolved to deliver copper to specific sites of utilization, 
thereby preventing the formation of potentially damaging free ionic copper in the 
cytoplasm. Copper uptake in mammalian cells is mediated by CTR1, a 
ubiquitously expressed homotrimeric transporter (151). Once in the cytoplasm, 
small cytoplasmic proteins known as copper chaperones deliver copper linearly 
to distinct target enzymes via direct protein-protein interactions. The copper 
chaperones, CCS and COX17 are involved in copper delivery to Cu/Zn 
superoxide dismutase in the cytoplasm (SOD1) and to cytochrome c oxidase 
(CCO) in the mitochondria, respectively (156, 179).  SCO1 and SCO2 are also 
 104 
involved in copper delivery to cytochrome c oxidase via a process that is poorly 
understood (205). The third target for copper delivery is the ATP7A protein (or 
closely related ATP7B protein), a copper transporter located in the Golgi complex 
that receives copper from the ATOX1 copper chaperone in the cytoplasm (1, 
159, 365). ATP7A transports copper into the Golgi lumen to supply copper to a 
select group of copper-dependent enzymes, which are either secreted from cells, 
or reside within vesicular compartments (232, 233, 235, 384). In addition to 
providing copper to secreted cuproenzymes, ATP7A is also responsible for 
copper export from cells. This export activity is associated with copper-stimulated 
trafficking of ATP7A to post-Golgi compartments, which include cytoplasmic 
vesicles and the plasma membrane (1). The trafficking of ATP7A is triggered 
when cytoplasmic copper levels are elevated (158), and this process requires 
both copper binding to cytoplasmic regions of the ATPase as well as its catalytic 
turnover (169, 228). These essential functions of the ATP7A protein are 
illustrated by Menkes disease, a lethal disorder of copper deficiency caused by 
ATP7A mutations (145).   
 
Despite advances in our understanding of the intracellular routes of copper 
transport, it is unknown whether copper is differentially allocated along the three 
chaperone-mediated pathways to its respective targets, or whether such a 
hierarchy is altered by certain physiological conditions. In this study, we 
demonstrate using cultured RAW264.7 macrophage cells that hypoxia results in 
profound changes in copper homeostasis including enhanced expression of 
CTR1 and ATP7A proteins, copper-stimulated trafficking of ATP7A to post-Golgi 
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compartments, increased copper delivery to ceruloplasmin, and depletion of 
alternative copper targets, CCS, SOD1, and COX1, the copper-binding subunit of 
cytochrome c oxidase. Both the trafficking of ATP7A and the activation of 
ceruloplasmin were dependent on the production of mitochondrial reactive 
oxygen species. These findings suggest that oxygen status can regulate copper 
allocation to the secretory pathway for hypoxia-induced cuproenzymes, and 
reveal hypoxia as a unique pathophysiological regulator of intracellular copper 
hierarchy.  
 
 
3.3 Materials and methods 
 
 
 
Reagents and Antibodies All reagents were from Sigma, unless otherwise 
indicated. The rabbit polyclonal Ctr-1 antibody (100) was a kind gift of Dennis 
Thiele (Duke University, Durham NC). The rabbit polyclonal ATP7A antibody 
raised against the C-terminal portion of the protein and was a generous gift of Dr. 
Elizabeth Eipper (252). Additional affinity purified anti-ATP7A antibodies were 
raised in rabbits against the synthetic peptide NH2-CDKHSLLVGDFREDDDTTL-
COOH (Bethyl Laboratories, Mongomery TX). Mouse anti-tubulin antibody, and 
secondary HRP-conjugated IgG antibodies were purchased from Roche 
Molecular Biochemicals. Monoclonal antibody against COX I, and rabbit and 
mouse IgG antibodies conjugated with fluoresecent Alexa-488 and Alexa-594 
were from Invitrogen (Carlsbad, CA). Antibodies against mouse GM130 and 
syntaxin-6 were purchased from BD Transduction Laboratories (San Jose, CA). 
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Antibodies against CD68 and HIF-1α were purchased from Serotec (Raleigh, 
NC) and Novus Biologicals (Littleton, CO) respectively. Antibodies against Cu/Zn 
SOD, CCS, and ceruloplasmin were purchased from Stressgen (383, 385), Santa 
Cruz Biotechnology (Santa Cruz, CA), and Abcam (Cambridge, MA), 
respectively.  
 
 
Cell Lines All cell lines were obtained from the American Type Culture 
Collection and were maintained in Dulbecco’s modified Eagle’s medium 
(Invitrogen) containing 10% (v/v) fetal bovine serum and 100 units/ml penicillin 
and streptomycin (Invitrogen) in 5% CO2 at 37°C. Primary macrophages were 
isolated by peritoneal lavage. C57BL/6J mice were injected with 0.5 ml of 
thioglycolate medium into the peritoneum to elicit macrophage infiltration. After 72 
h, macrophages were isolated by peritoneal lavage using ice-cold PBS. Cells 
were seeded in six-well trays for each experiment, as described below. Hypoxia 
experiments were conducted at 37oC using a hypoxic incubator in which oxygen 
levels were lowered by air displacement with N2 and CO2 gas. Mitochondrial 
DNA-depleted RAW/Rho- cells were generated by culturing RAW264.7 cells for 
26 days in media supplemented with 1 mM sodium pyruvate in the presence of 
50 ng/ml ethidium bromide and confirmed by the loss of mitochondria-encoded 
cytochrome c oxidase subunit I (COX-1) protein from mitochondrial extracts. 
RNAi-mediated silencing of ATP7A in RAW264.7 cells was performed as 
described in Chapter 2. Lipofectamine 2000 (Invitrogen) was used in all 
transfections.  
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Copper uptake Radioactive copper (64Cu) was purchased from the Mallinckrodt 
Institute of Radiology, Washington University (Saint Louis, MO). Cells were pre-
cultured in triplicate for 72 h in 6-well trays under either normoxic (21% O2) or 
hypoxic (4% O2) conditions, exposed to 1 µM 64Cu for 5 min, washed extensively 
in ice-cold PBS and radioactivity was measured using a gamma counter. Counts 
were normalized against total protein. 
 
 
Immunological techniques and PC-3 tumor growth Immunofluorescence 
microscopy and Western blot analysis were performed as described in Chapter 
2. PC-3 prostate carcinoma cells (5 x 106) were injected subcutaneously in one 
flank of each anesthetized four-week-old ICRSC-M SCID outbred mice obtained 
from Taconic (Germantown, NY). Mice were maintained in an approved 
pathogen-free institutional housing. Animal studies were conducted as outlined in 
the NIH Guidelines for the Care and Use of Laboratory Animals and the Policy 
and Procedures for Animal Research of the Harry S. Truman Veterans Memorial 
Hospital. Over a period of 4 weeks solid tumors of approximately 1-cm diameter 
were excised from anesthetized SCID mice and flash frozen in fixative. Frozen 
tumors were cryosectioned, fixed in acetone for 10 minutes, washed in 
phosphate buffered saline (PBS) and blocked overnight in 1% (w/v) casein 
buffer. Immunostaining was performed using antibodies against ATP7A, CD68 
and HIF-1α overnight, followed by staining with Alexa 488-conjugated anti-rabbit 
and Alexa 594-conjugated anti-mouse IgG antibodies for one hour. Nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI). 
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Enzyme Assays  Cytochrome c oxidase activity assays were performed using 
mitochondrial preparations from RAW264.7 cells. Cells were grown in 75-cm2 
flasks and scraped using ice-cold PBS. Mitochondrial fractions were collected 
using the Cell Mitochondria Isolation Kit from Sigma. Cytochrome c oxidase 
activity was assessed using the Cytochrome c Oxidase Assay Kit from Sigma. 
Cytochromes c oxidase activity was normalized against mitochondrial protein 
content. For the cytochrome c oxidase subunit I immunoblot, mitochondrial 
extracts were fractionated on 4-20% (w/v) SDS-PAGE gels and probed with anti-
COX-1. Superoxide dismutase assays were performed as described previously 
(386, 387). RAW264.7 cell lysates were fractionated using nondenaturing 12% 
(w/v) polyacrylamide gel electrophoresis and superoxide dismutase activity was 
detected by incubation of gels in nitro blue tetrazolium at room temperature. 
Ceruloplasmin activity in concentrated conditioned media was determined by its 
p-phenylenediamine oxidase activity, as previously described (179). RAW264.7 
cells were grown in 6-well plates and conditioned media were collected and 
concentrated using Amicon Ultra-4 filter tubes (Millipore). Ceruloplasmin activity 
was normalized against total protein content in the cell pellets. Ceruloplasmin 
protein levels were detected in concentrated media using immunoblot analysis.  
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3.4 Results 
 
 
 
Oxygen limitation stimulates the expression of CTR1 and ATP7A copper 
transporters in macrophages We began this study by investigating the 
relationship between oxygen availability and copper homeostasis in the 
macrophage cell line, RAW264.7. Macrophages are phagocytotic cells of the 
adaptive immune system that are commonly recruited to hypoxic tissues. 
Exposure of RAW264.7 macrophages to mild hypoxia (4% O2) increased copper 
uptake relative to normoxia (21% O2) (Fig. 3.1A). Consistent with this increase in 
copper uptake, hypoxia stimulated the expression of the CTR1 protein within    
24 h relative to normoxia (21% O2) (Figs. 3.1B, and 3.1C). Interestingly, the 
expression of the ATP7A copper transporter in RAW264.7 cells and primary 
peritoneal macrophages was also stimulated by hypoxia, although the rate of 
induction was slower than for CTR1 (Fig. 3.2A, and 3.2B).  
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FIGURE 3.1. Hypoxia alters copper homeostasis in RAW264.7 
macrophages. A, Copper uptake activity. RAW264.7 cells were pre-exposed to 
normoxia (21% O2) or hypoxia (4% O2) for 72 h and copper uptake in the 
presence of 1 µM 64Cu was measured over 5 min and normalized against total 
protein (mean + SD; n = 3). B-C, The effect of hypoxia on CTR1 protein levels in 
RAW264.7 cells and thioglycollate-elicited primary peritoneal macrophages 
(TPECs) under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions.  B, 
Immunoblot analysis of Ctr1 protein in lysates from normoxic and hypoxic 
RAW264.7 cells, and C, cultured primary peritoneal macrophages. Tubulin was 
detected as a loading control. 
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Fig. 3.1 
 
 
 
 
CTR1 
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FIGURE 3.2. Hypoxia increases the expression of ATP7A in macrophages. 
Effect of hypoxia on ATP7A protein levels in RAW264.7 cells and primary 
peritoneal macrophages under normoxic (N; 21% O2) or hypoxic (H; 4% O2) 
conditions. A, Immunoblot analysis of ATP7A protein in lysates from normoxic 
and hypoxic RAW264.7 cells, and B, cultured primary peritoneal macrophages. 
Tubulin was detected as a loading control. 
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Fig. 3.2 
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Hypoxia stimulates copper-dependent trafficking of the ATP7A protein in 
RAW264.7 macrophages Since the trafficking of ATP7A from the trans-Golgi 
network is known to be triggered by increased copper delivery to this transporter 
(1), we investigated whether reduced oxygen tension might alter the localization 
of the ATP7A copper transporter in the murine macrophage cell line, RAW264.7. 
The relocalization of ATP7A from the trans-Golgi network is a key biological 
indicator of increased cytoplasmic copper availability and has been documented 
in several different cell types (1, 71, 388). Using immunofluorescence 
microscopy, the ATP7A protein was localized within the perinuclear region of 
RAW264.7 cells exposed to normoxic conditions (21% O2), consistent with its 
location in the trans-Golgi network (Fig. 3.3A). As expected, treatment of these 
cells with copper resulted in the trafficking of ATP7A from the perinuclear region 
to cytoplasmic vesicles (Fig. 3.3A). Significantly, when these cells were exposed 
to chronic hypoxia (4% O2 for 96 h), the ATP7A protein was also dispersed to 
post-Golgi vesicles (Fig. 3.3A). This redistribution of the ATP7A protein required 
at least 48 h of hypoxia and was not accelerated by lower levels of oxygen (data 
not shown). The return of hypoxic cells to normoxic conditions restored the 
location of the ATP7A protein to the perinuclear region, indicating that the effect 
of hypoxia on ATP7A was reversible (Fig. 3A). The intracellular location of the 
trans-Golgi marker protein, syntaxin 6, and the Golgi matrix protein, GM130, 
were not altered by hypoxia in RAW264.7 cells (Fig. 3.3B, and 3.3C), suggesting 
that the effects of hypoxia on ATP7A were not the result of a general alteration of 
Golgi structure. These hypoxic conditions did not alter the viability of RAW264.7 
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cells, which could be passaged continuously at 4% oxygen (data not shown). 
Interestingly, ATP7A trafficking to post-Golgi compartments in response to 
hypoxia was not observed in a range of other cells types, including N2a, NIH3T3, 
DLD1, HT1080 (Fig. 3.13), HEK293, HeLa, NRK, human primary aorta 
endothelial cells (HAEC), and rat primary smooth muscle cells (SMC) (not 
shown).   
 
We further tested whether the membrane-permeable copper chelator, 
tetrathiomolybdate, could suppress ATP7A trafficking to post-Golgi in response 
to hypoxia in RAW264.7 cells. As shown in Figure 3.3D, TTM inhibited ATP7A 
relocalization in response to hypoxia. These findings support the hypothesis that 
oxygen limitation increases copper binding to the ATP7A protein resulting in its 
trafficking from the Golgi. 
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FIGURE 3.3. Hypoxia stimulates trafficking of the ATP7A protein.                
A, Immunofluorescence analysis of ATP7A protein in RAW264.7 cells grown 
under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions for 96 h. 
Relocalization of the ATP7A protein from the perinuclear region is shown in 
hypoxic cells and normoxic cells exposed to copper (second panel). Restoration 
of perinuclear labeling of ATP7A occurred upon the transfer of hypoxic cells to 
normoxic media for 30 min (fourth panel). Cells were fixed, permeabilized and 
probed with antibodies against for ATP7A and anti-rabbit IgG antibodies 
conjugated to Alexa-488 (green).  Nuclei were labeled with DAPI (blue). B-C, 
Analysis of Golgi marker proteins in hypoxic RAW264.7 cells. RAW264.7 cells 
were cultured under hypoxic or normoxic conditions as described in (A) and 
probed using antibodies against the trans-Golgi network marker protein Syntaxin 
6 (B), and the Golgi matrix protein, GM130 (C). Nuclei were labeled with DAPI 
(blue). D, Hypoxia-induced trafficking of ATP7A to post-Golgi compartments is 
inhibited by the copper chelator, tetrathiomolybdate.  RAW264.7 cells were 
cultured under hypoxic or normoxic conditions as described in (A), in the 
presence or absence of tetrathiomolybdate (TTM, 5 nM).  ATP7A protein was 
detected as described in (A). 
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Fig. 3.3 
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Hypoxia stimulates trafficking of the ATP7A protein in tumor-associated 
macrophages Since previous studies have demonstrated that macrophages 
are recruited to the hypoxic regions of solid tumors (reviewed in (389)), the use of 
a human prostate tumor xenograft provided an opportunity to investigate the 
intracellular distribution of ATP7A in hypoxic macrophages in vivo. The 
tumorigenic human prostate cell line, PC-3, was chosen for these studies since 
ATP7A expression is very low in these cells, thus allowing for easy identification 
of ATP7A in tumor-associated macrophages. PC-3 tumors were grown in nude 
mice to approximately 2-cm diameter, excised and cryosectioned. 
Immunofluorescence analysis of ATP7A expression in PC-3 tumors 
demonstrated that there was abundant expression in macrophages identified 
using the macrophage-specific marker CD-68 (Figure 3.4A). As expected, there 
was little if any ATP7A expression in PC-3 tumor cells. Consistent with previous 
studies, these tumor-associated macrophages were concentrated at the tumor 
edges, with occasional infiltration into the tumor body (390-392). Significantly, we 
noticed that in some macrophages the location of ATP7A was restricted to the 
Golgi complex, whereas in other macrophages it appeared to be relocalized in a 
manner reminiscent of the trafficking seen in cultured RAW264.7 cells (Figure 
3.4A, lower panel; arrows). Further analysis demonstrated that ATP7A was 
dispersed only in macrophages that co-expressed the HIF-1α protein (Figure 
3.4B), a key transcriptional regulator of hypoxic gene responses whose 
abundance is increased in tumor-associated macrophages (393, 394). These 
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findings provide evidence that the hypoxia-stimulated trafficking of ATP7A occurs 
in macrophages in vivo.  
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FIGURE 3.4. ATP7A trafficking in HIF-1α-positive macrophages in tumor 
xenografts. A, ATP7A is strongly expressed in tumor-associated macrophages. 
Human prostate cell PC-3 tumors from SCID mice were cryosectioned and 
probed with antibodies against ATP7A (green) or antibodies against the 
macrophage marker CD68 (red). Upper panels are a low power magnification 
showing both the tumor mass and tumor edge (x200).  Note the propensity of 
ATP7A and CD68 staining in cells associated with the tumor edge. A higher 
magnification of the tumor edge region reveals extensive co-expression of 
ATP7A in CD68-positive macrophages, as indicated by yellow signal in the 
merged image. Nuclei were stained using DAPI (blue).  Arrow and arrowhead 
(lower left panel) reveals heterogeneous localization of the ATP7A in 
macrophages, in either a perinuclear or dispersed distribution. B, The dispersed 
distribution of the ATP7A occurs in HIF-1α-positive macrophages. PC-3 cell 
tumors were immunostained for ATP7A (green) and HIF-1α (red). ATP7A was 
restricted to the perinuclear region of cells negative for HIF-1α expression 
(arrows), whereas a dispersed distribution of ATP7A was detected in cells that 
were positive for HIF-1α (arrow heads) (x600). 
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Fig. 3.4 
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Hypoxia stimulates copper transport to ceruloplasmin via ATP7A The major 
function of ATP7A is to pump copper into the secretory pathway and supply 
copper to secreted cuproenzymes. We hypothesized that a potential target for 
this copper delivery in response to hypoxia might be ceruloplasmin, a 
cuproenzyme that depends on copper delivery for its activity. Ceruloplasmin is a 
ferroxidase secreted from macrophages and hepatocytes whose expression and 
activity are stimulated by hypoxia (146, 314, 395). Hypoxia was found to increase 
both the abundance and activity of ceruloplasmin secreted into the culture 
medium of RAW264.7 cells relative to normoxia (Figs. 3.5A, and 3.5B). To 
examine whether the increase in ceruloplasmin activity was dependent on 
ATP7A copper transport activity, we measured ceruloplasmin activity in the 
ATP7A-depleted cell line (described in Chapter 2). Compared to control cells, 
ceruloplasmin activity in ATP7A-RNAi cells was markedly reduced under hypoxic 
conditions suggesting that ATP7A copper transport activity was required for 
copper delivery to ceruloplasmin (Fig. 3.5D). Consistent with this postulate, the 
addition of copper to the media of these cells bypassed the requirement for 
ATP7A and restored ceruloplasmin activity, indicating that the effect of ATP7A 
gene silencing was due to a blockage of copper delivery to ceruloplasmin (Fig. 
3.5D). Control experiments indicated that ATP7A silencing did not alter 
ceruloplasmin protein levels in the medium relative to control cells in either 
hypoxic or normoxic conditions (Fig. 3.5C). Taken together with our earlier 
results, these findings suggest that hypoxia stimulates an increase in copper 
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delivery to ceruloplasmin via increases in CTR1-mediated copper uptake as well 
as ATP7A-dependent copper delivery into secretory compartments. 
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FIGURE 3.5. The stimulation of ceruloplasmin activity by hypoxia is 
dependent on the ATP7A protein. A, Ceruloplasmin (Cp) abundance in 
hypoxia. Conditioned media was collected from RAW264.7 cells grown under 
normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions for the indicated times. 
The media was concentrated and subjected to non-denaturing SDS-PAGE and 
immunoblot analysis with anti-Cp antibody. Immunoblot of tubulin from 
corresponding cell lysates is shown. Lane 1 shows ceruloplasmin levels in 
concentrated growth media alone (M). B, Analysis of ceruloplasmin activity. 
Ceruloplasmin activity (p-phenylenediamine oxidase activity) was determined in 
the concentrated conditioned media from RAW264.7 cells following exposure to 
normoxia (N; 21% O2) or hypoxia (H; 4% O2) for 72 h. Activity was normalized 
against total protein content of the corresponding cell lysates (mean + SD; n = 3). 
C, Cp abundance in conditioned media from ATP7A-RNAi and control-RNAi 
RAW264.7 cells following exposure to normoxia (N; 21% O2) or hypoxia (H; 4% 
O2) for 72 h. The media was concentrated and subjected to non-denaturing SDS-
PAGE and immunoblot analysis with anti-Cp antibody. Immunoblot of tubulin 
from corresponding cell lysates is shown. D, Ceruloplasmin activity was 
assessed in conditioned media from ATP7A-RNAi, ATP7A-RNAi + 20 µM CuCl2, 
or control-RNAi RAW264.7 cell lines, as described in (B) (mean + SD; n = 3). 
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Fig. 3.5 
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Hypoxia alters copper metabolic pathways in hypoxic macrophages As 
mentioned earlier, intracellular copper delivery to cuproenzymes occurs via three 
copper known chaperone-mediated pathways, namely CCS to SOD1, COX17 to 
CCO, and ATOX1 to ATP7A. To further characterize the impact of hypoxia on 
copper metabolism, we tested whether the abundance and activities of SOD1 
and CCO were altered in hypoxic RAW264.7 macrophages. The activity of SOD1 
was reduced after 48 h exposure to 4% O2 and completely abolished by 96 h 
(Figure 3.6A, upper panel). This was also accompanied by a reduction in the 
levels of both the SOD1 and CCS proteins over the same time period (Figure 
3.6A lower panel and 3.6B). The activity of CCO was also markedly reduced in 
mitochondrial preparations isolated from hypoxic RAW264.7 macrophages 
(Figure 3.7A), and this was accompanied by the decreased expression of  the 
COX1 subunit of CCO which contains the CuB copper binding site (Fig. 3.7B). 
Together with the above experiments, these findings suggest that hypoxia 
suppresses copper delivery to SOD1 and CCO in RAW264.7 macrophages, and 
enhances copper delivery to the ATP7A/ceruloplasmin pathway. 
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FIGURE 3.6. Hypoxia alters the CCS/SOD pathway in RAW264.7 
macrophages. A, Effect of hypoxia on SOD1 protein expression and activity. 
RAW264.7 cells were grown under normoxic (N; 21% O2) or hypoxic (H; 4% O2) 
conditions for the indicated times. Cell lysates were subjected to non-denaturing 
SDS-PAGE for the in-gel SOD1 activity assay (top panel).  Immunoblots from the 
same lysates were probed with anti-SOD1 antibodies to detect SOD1 protein 
(lower panel). Tubulin was detected as a loading control. B, Effect of hypoxia on 
the abundance of CCS, the copper-chaperone for SOD1.  The same lysates as in 
(A) were subjected to SDS-PAGE and immunoblot analysis with anti-CCS 
antibodies.  
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Fig. 3.6 
 
 129 
FIGURE 3.7. Hypoxia alters cytochrome c oxidase expression and activity 
in RAW264.7 cells. A, Analysis of cytochrome c oxidase activity in hypoxic 
(shaded bars) and normoxic (solid bars) conditions. Activity was measured in 
mitochondrial preparations isolated from RAW264.7 cells cultured under 
normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions for the indicated times. 
Values were normalized against total mitochondrial protein (mean + SD; n = 3).  
*p<0.05. B, Analysis of COX1 protein levels. Mitochondrial preparations from (A) 
were subjected to SDS-PAGE and probed with antibodies against COX1, the 
copper-binding subunit I of the cytochrome c oxidase complex. Immunoblots 
were probed with an antibody against mouse porin to indicate protein loading. 
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Fig. 3.7 
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The hypoxia-induced trafficking of ATP7A and ceruloplasmin activation are 
dependent on mitochondria and reactive oxygen species  Recent studies have 
demonstrated that the mitochondria are an important sensor of oxygen limitation 
in mammalian cells. Mitochondrial oxygen sensing involves the generation 
reactive oxygen species (ROS) by the respiratory complex III of the electron 
transport chain which are required for the stabilization and activation of HIF-1α, 
the master transcriptional regulator of hypoxic responses (393, 394). To test 
whether ROS are required for the hypoxia-induced trafficking of ATP7A, we 
investigated whether a membrane-permeable antioxidant could suppress this 
trafficking process. Ebselen treatment of RAW264.7 cells prevented the hypoxia-
induced trafficking of ATP7A (Fig. 3.8A). This suppression of ATP7A trafficking 
by Ebselen was not due to an inhibition of the trafficking machinery because the 
addition of copper elicited ATP7A trafficking in Ebselen-treated cells (Fig. 3.8A). 
Moreover, the addition of the oxidizing agent hydrogen peroxide to RAW264.7 
cells under normoxic conditions also resulted in ATP7A trafficking (Fig. 3.8B). 
These findings suggest that reactive oxygen species generated by hypoxia are 
involved in ATP7A trafficking in RAW264.7 cells. Since the increase in 
ceruloplasmin activity during hypoxia requires the delivery of copper to the 
enzyme via ATP7A, we hypothesized that, along with inhibiting the trafficking of 
ATP7A, Ebselen would also inhibit the increase in ceruloplasmin activity in 
hypoxic macrophages. Indeed, as shown in Figure 3.8C, Ebselen suppressed the 
increase in ceruloplasmin activity associated with hypoxia, an effect that was 
overcome by the addition of copper to the Ebselen-treated cells. Interestingly, 
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Ebselen treatment did not inhibit the hypoxia-induced increase in CTR1 and 
ATP7A expression (Fig. 3.10A, and 3.10B) nor the suppression of the CCS/SOD 
(Fig. 3.11) and COX (Fig. 3.12) activities associated with hypoxia. 
 
Next, we investigated the contribution of mitochondria-generated ROS to the 
hypoxia-induced ATP7A trafficking. Rho-minus RAW264.7 cells (RAW/Rho-) 
lacking functional mitochondria were isolated by selection in ethidium bromide, 
and the depletion of the mitochondria-encoded protein, COX-1, but not the 
nuclear-encoded mitochondrial protein, porin was detected (Fig. 3.9A). 
Significantly, the trafficking of ATP7A to post-Golgi in response to hypoxia was 
suppressed in RAW/Rho- cells suggesting that this process is dependent on 
mitochondria (Fig. 3.9B). The ATP7A trafficking machinery was not compromised 
in the RAW/Rho- cells because exogenous copper was able to stimulate ATP7A 
trafficking. Ceruloplasmin activation under hypoxic conditions, shown earlier to 
be ATP7A-dependent, was also suppressed in RAW/Rho- cells exposed to 
hypoxia, but not when copper was provided to the media (Fig. 3.9C). Taken 
together, these findings suggest that mitochondrially-generated ROS may 
facilitate the delivery of copper to ATP7A during hypoxia, thereby mediating 
ATP7A-dependent copper transport to ceruloplasmin. 
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FIGURE 3.8. The hypoxia-induced trafficking of ATP7A and activation of 
ceruloplasmin are mediated by reactive oxygen species. A, RAW264.7 cells 
were exposed to normoxia or hypoxia for 96 h ±10 µM Ebselen and/or 20 µM 
CuCl2. Immunofluorescence staining shows ATP7A in green. B, RAW264.7 cells 
were exposed for 2 h to hydrogen peroxide (H2O2, 500 µM). ATP7A is shown in 
green. C, Ceruloplasmin activity in conditioned media of RAW264.7 cells 
exposed to normoxia or hypoxia for 72 h ±10 µM Ebselen and/or 20 µM CuCl2. 
Ceruloplasmin activity values were normalized against total protein content of 
corresponding cell lysates (mean + SD; n = 3). Different letters above each value 
indicate significant differences p<0.05. 
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FIGURE 3.9. The hypoxia-induced trafficking of ATP7A and activation of 
ceruloplasmin are mediated by reactive oxygen species generated in the 
mitochondria. RAW264.7 cells were treated with ethidium bromide to deplete 
their mitochondrial DNA and designated RAW/Rho-. A, Immunoblot of COX-1 
from mitochondrial extracts of RAW264.7 and RAW/Rho- cells shows loss of 
expression of mitochondrially-encoded COX-1 in RAW/Rho- cells. Porin was 
detected as loading control. B, Immunofluorescence imaging of ATP7A in 
RAW264.7 and RAW/Rho- cells exposed to normoxia or hypoxia for 96 h ± 20 
µM CuCl2. C, Ceruloplasmin activity was measured in conditioned media of 
RAW264.7 and RAW/Rho- cells exposed to normoxia or hypoxia for                  
72 h ± 20 µM CuCl2. Values were normalized against total protein content of 
corresponding cell lysates (mean + SD; n = 3). Different letters above each value 
indicate significant differences p<0.05. 
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FIGURE 3.10. Ebselen does not inhibit the increases in CTR1 and ATP7A 
protein expression associated with hypoxia. RAW264.7 cells were cultured 
under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions ± 50 µM Ebselen. 
Immunoblot analysis of A, CTR1 protein and B, ATP7A protein. Tubulin was 
detected as a loading control. 
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FIGURE 3.11. Ebselen does not inhibit the hypoxia-induced changes in 
CCS/SOD pathway in RAW264.7 macrophages. RAW264.7 cells were cultured 
under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions ± 50 µM Ebselen. 
A, Cell lysates were subjected to non-denaturing SDS-PAGE for the in-gel SOD1 
activity assay (top panel).  Immunoblots from the same lysates were probed with 
anti-SOD1 antibodies to detect SOD1 protein (lower panel). B, The same lysates 
as in (A) were subjected to SDS-PAGE and immunoblot analysis with anti-CCS 
antibodies. Tubulin was detected as a loading control. 
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FIGURE 3.12. Ebselen does not inhibit the hypoxia-induced changes in the 
cytochrome c oxidase pathway in RAW264.7 macrophages. RAW264.7 cells 
were cultured under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions ± 50 
µM Ebselen. A, Analysis of COX1 protein levels. Mitochondrial preparations were 
isolated from RAW264.7 cells cultured under normoxic (N; 21% O2) or hypoxic 
(H; 4% O2) conditions for 72 h and subjected to SDS-PAGE and probed with 
antibodies against COX1, the copper-binding subunit I of the cytochrome c 
oxidase complex. Immunoblots were probed with an antibody against porin to 
indicate protein loading. B, Analysis of cytochrome c oxidase activity in hypoxic 
(shaded bars) and normoxic (solid bars) conditions. Activity was measured in 
mitochondrial preparations from (A). Values were normalized against total 
mitochondrial protein (mean + SD; n = 3).  *p<0.05.  
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Effect of hypoxia on the copper pathways in non-macrophage cell lines  We 
investigated whether the observed changes in copper pathways induced by 
hypoxia in macrophage cells also occur in other cell lines. Interestingly, ATP77A 
did not traffic to post-Golgi in response to hypoxia in N2a, NIH3T3, DLD1, 
HT1080 cells (Fig. 3.13), HEK293, human primary aortic endothelial cells 
(HAECs), and rat primary smooth muscle cells (SMCs) (not shown). 
Furthermore, hypoxia did not induce the coordinated increases in CTR1 and 
ATP7A protein expression, along with the suppression of the activities of the two 
other copper pathways, i.e. the CCS/SOD and the cytochrome c oxidase 
pathways in any of the cell lines tested (Fig. 3.14, 3.15, and 3.16). These 
observations suggest that the observed changes in copper homeostasis in 
response to hypoxia are unique to macrophages. Further studies are required to 
determine whether these effects also occur in other cells of the myeloid lineage.  
It is worth noting that although hypoxia did not induces changes in the copper 
pathways in N2a cells that were similar to those observed in macrophage cells, 
there were some interesting changes that may be of relevance to neuron biology. 
In response to hypoxia, the expression of CTR1, CCS, SOD1, as well as the 
activity of SOD1 were induced in N2a cells.  
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FIGURE 3.13. ATP7A does not traffic in response to hypoxia in various cell 
lines. Immunofluorescence analysis of ATP7A protein in in N2a, NIH3T3, DLD1, 
and HT1080 cells grown under normoxic (N; 21% O2) or hypoxic (H; 4% O2) 
conditions for 96 h. Cells were fixed, permeabilized and probed with antibodies 
against ATP7A and anti-rabbit IgG antibodies conjugated to Alexa-488 (green). 
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FIGURE 3.14. Effect of hypoxia on CTR1 and ATP7A protein expression 
levels in various cell lines. N2a, NIH3T3, DLD1, HT1080 and HEK293 cells 
were cultured under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions. 
Immunoblot analysis of A, CTR1 protein and B, ATP7A protein. Tubulin was 
detected as a loading control. CTR1 protein levels were too low to detect in N2a, 
NIH3T3 and HEK293 cells. 
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Fig. 3.14 
 
 
 148 
FIGURE 3.15. Effect of hypoxia on the CCS/SOD pathway in various cell 
lines. N2a, NIH3T3, DLD1, HT1080 and HEK293 cells were cultured under 
normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions. A, Cell lysates were 
subjected to non-denaturing SDS-PAGE for the in-gel SOD1 activity assay (top 
panel).  Immunoblots from the same lysates were probed with anti-SOD1 
antibodies to detect SOD1 protein (lower panel). B, The same lysates as in (A) 
were subjected to SDS-PAGE and immunoblot analysis with anti-CCS 
antibodies. Tubulin was detected as a loading control. 
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FIGURE 3.16. Effect of hypoxia on the cytochrome c oxidase pathway in 
various cell lines. N2a, NIH3T3, DLD1, HT1080 and HEK293 cells were 
cultured under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions. A, 
Analysis of COX1 protein levels. Mitochondrial preparations isolated from cells 
cultured under normoxic (N; 21% O2) or hypoxic (H; 4% O2) conditions were 
subjected to SDS-PAGE and probed with antibodies against COX1, the copper-
binding subunit I of the cytochrome c oxidase complex. Immunoblots were 
probed with an antibody against porin to indicate protein loading. B, Analysis of 
cytochrome C oxidase activity in hypoxic (shaded bars) and normoxic (solid bars) 
conditions. Activity was measured in mitochondrial preparations from (A). Values 
were normalized against total mitochondrial protein (mean + SD; n = 3).  *p<0.05.  
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3.5 Discussion 
 
 
 
Hypoxia, or relative O2 depletion, is a serious condition that threatens cell 
survival, and can cause severe organ damage and injury in human disease. 
Respiratory failure, systemic hypotension and ischemia promote hypoxic tissue 
injury in great part mediated by oxidative stress (133-138). Therefore, 
physiological and cellular responses have evolved to defend the oxygen supply 
(139-142). Rapid responses are required on the cellular level to protect the cell 
from prolonged O2 depletion. These responses are mediated by the hypoxia-
inducible factor transcription factor 1 alpha (HIF-1α), and lead to the upregulation 
of genes involved in glucose uptake, cell survival, cytoskeletal organization, 
extracellular matrix remodeling, vascular tone, iron metabolism, and apoptosis 
(290-294). On the physiological level, responses to limitations in O2 supply 
ultimately result in vascular remodeling, cell migration and proliferation, and 
formation of new blood vessels or angiogenesis. 
 
Macrophage cells commonly encounter hypoxia as they migrate away from the 
vasculature, therefore, these cells have developed unique adaptive mechanisms 
allowing them to function in a hostile environment. We have identified a series of 
unexpected changes in macrophage intracellular copper metabolism in response 
to hypoxia, as illustrated by the model in Figure 3.17. These include the elevated 
expression of the CTR1 copper transporter and increased copper uptake; a 
decrease in the abundance and/or activity of CCS, SOD1 and CCO; and 
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increased copper delivery to ATP7A and ceruloplasmin in the secretory pathway.  
Significantly, such changes provide the first evidence that the hierarchy of 
intracellular copper distribution is subject to modulation by environmental stimuli.   
 
Our findings suggest that this coordinate reprogramming of copper metabolism 
functions to enhance copper availability to the ATP7A protein for copper delivery 
to the secretory pathway. This was evidenced by the requirement for ATP7A for 
ceruloplasmin activation in response to hypoxia as well as the copper-dependent 
relocalization of the ATP7A protein from the TGN to a post-Golgi compartment, a 
well-described indicator of increased copper flux to ATP7A. Ceruloplasmin is a 
ferroxidase synthesized in the liver and macrophages that plays a critical role in 
cellular iron export by oxidizing iron, a necessary step in the iron loading of 
transferrin in the blood (396).  This function of ceruloplasmin is particularly critical 
during hypoxia where the mobilization of iron into the blood is important for 
hematopoeisis (146).    
 
Further evidence for a shift in the intracellular hierarchy of copper metabolism in 
response to hypoxia was our finding of decreased levels of CCS protein and 
SOD1 activity. By diminishing the flux of copper from CCS to SOD1, this would 
allow more copper to be conserved for the ATP7A protein.  Whether such 
adaptations respond directly to reduced oxygen levels is unknown, however, 
CCS degradation may be triggered in hypoxic macrophages in response to the 
higher copper uptake activity (Fig. 3.1), since elevated intracellular copper 
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concentrations are known to cause CCS degradation in other cells (185). Like 
SOD1, the activity of cytochrome c oxidase was also diminished by hypoxia in 
RAW264.7 cells and this was associated with a decrease in COX1 protein levels, 
the CuB-site containing subunit of cytochrome c oxidase. A decrease in 
cytochrome c oxidase activity has been observed in hypoxic macrophages in 
previous studies as part of a metabolic shift from oxidative phosphorylation to 
glycolysis for the bulk of ATP production (397, 398). By eliminating intracellular 
copper delivery to COX1, this may serve the dual purpose of preventing wasteful 
copper delivery to cytochrome c oxidase as the cell undergoes a metabolic shift 
to glycolysis, as well as diverting precious copper stores to secretory 
compartments via ATP7A. 
 
A particularly notable finding of this study was the requirement for reactive 
oxygen species and mitochondrial function for both the activation of 
ceruloplasmin in hypoxic RAW264.7 macrophages, and the induction of ATP7A 
trafficking. Recent studies indicate that the mitochondria are a critical sensor of 
oxygen in mammalian cells and communicate this information to a master 
regulator of hypoxia-responsive gene expression, the HIF-1α protein (139, 321, 
324, 325, 340-344). HIF-1α is constitutively degraded under oxygen-replete 
conditions, however, the stimulated production of ROS at complex III of the 
mitochondrial electron transport chain is essential for HIF-1α stabilization under 
hypoxic conditions (139, 321, 324, 325, 340-344). Based on these findings, the 
ability of mitochondrial ROS to stimulate ceruloplasmin activity and ATP7A 
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trafficking may occur via a HIF-1α-dependent mechanism. Alternatively, the ROS 
may function indirectly by displacing labile copper ions from intracellular ligands, 
thereby increasing copper availability for ATP7A. Although this latter mechanism 
would be the first such type of ROS-mediated regulation of copper homeostasis 
in mammalian cells, a precedent exists in yeast where nitric oxide alters copper 
homeostasis by displacing copper from the AceI transcription factor (35). Other 
examples of ROS-mediated regulation of iron and zinc homeostasis also exist. 
For example, NO and H2O2 can displace iron from the IRP1/2 proteins, thereby 
allowing these proteins to regulate a select group of mRNAs encoding proteins 
involved in iron homeostasis (36-39). In the case of zinc, several studies have 
demonstrated that NO and H2O2 release labile zinc from metallothionein which 
then stimulates the activity of the metal-responsive transcription factor, MTF-1, a 
major regulator of zinc homeostasis (40, 41). Interestingly, the ROS generated 
during hypoxia in macrophage cells did not mediate the downregulation of the 
CCS/SOD and COX17/CCO pathways. Further studies are required to elucidate 
the mechanisms by which hypoxia downregulates these copper pathways.  
 
It appears that the above reported changes in copper homeostasis are somewhat 
unique to macrophages. ATP7A trafficking and/or changes in SOD1 and CCO 
activity were not observed in our analysis of cultured cells from a variety of 
sources including HeLa (cervical carcinoma), HEK293 (human embryonic 
kidney), N2a (neuroblastoma), primary human aortic endothelial cells, and 
primary rat smooth muscle cells. The reasons for this are not fully understood. 
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The macrophage-specific effects of hypoxia on copper homeostasis may be 
attributable to inflammatory responses, which in these cells overlap with 
responses to hypoxia (42, 43). Consistent with this postulate, our studies 
demonstrate that pro-inflammatory agents can stimulate copper-dependent 
ATP7A trafficking in macrophages under normoxic conditions.  
 
Macrophages are highly adapted to hypoxic environments and are prominent in 
avascular sites of diseased tissue, and the hypoxic regions of different types of 
tumors (391). By releasing pro-angiogenic cytokines that promote vascularization 
of hypoxic tissues, macrophages promote tissue repair and tumor growth (44-
47). This property is thought to underlie the positive relationship that exists 
between the macrophage content of tumors and a poor clinical outcome (48-53). 
It is, therefore, intriguing that copper also possesses pro-angiogenic and 
tumorigenic properties, and several studies have demonstrated that copper 
chelation is an effective suppressor of tumor vascularization and growth (54-57). 
Whether the adaptive changes in macrophage copper metabolism described in 
this study underlie copper’s role in tumor growth is unknown, and the subject of 
on-going experiments. 
 
The prioritization of copper distribution to ATP7A is a finding that is novel in 
mammals, but has parallels in microorganisms. For example, in the 
photosynthetic microbe Chlamydomonas reinhardtii, the copper-containing 
protein plastocyanin is degraded in response to copper-deficiency, which is 
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thought to be an adaptive process to preserve copper for more critical enzymes 
such as cytochrome c oxidase (399). It will be of interest to determine whether 
redistribution of intracellular copper is stimulated by pathophysiological 
conditions in other mammalian cell types. For example, copper is required for 
melanin production via tyrosinase, norepinephrine synthesis via dopamine b 
hydroxylase, and collagen cross-linking via lysyl oxidase, and the activity of each 
of these biochemical pathways can be initiated by several physiological or 
developmental cues in specific cell types (reviewed in (4)). The challenge of 
future studies will be to address whether this adaptive upregulation of 
cuproenzyme activity is achieved via adaptive changes in pathways that 
intracellular copper distribution. 
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FIGURE 3.17. Schematic model of macrophage copper homeostasis 
pathways altered by hypoxia. Effects of hypoxia (H) on specific steps in 
intracellular copper handing are shown based on the findings of this study. 
Hypoxia-stimulated expression of the CTR1 copper importer and copper uptake 
(1). Hypoxia-stimulated decrease in CCS expression (2) and activity of SOD1 (3). 
Mitochrondrial CCO activity was diminished by hypoxia associated with reduced 
expression of COX1 (4). The hypoxia-induced increase in ATP7A expression (5), 
copper-dependent trafficking of ATP7A (6), and ATP7A-dependent copper 
transport to ceruloplasmin (7), are ROS-dependent (8,9). 
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Fig. 3.17 
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CHAPTER 4 
 
 
 
SUMMARY AND FUTURE PERSPECTIVES 
 
 
4.1 ATP7A-mediated copper transport into the phagosome enhances the 
bactericidal activity of macrophages. 
 
 
Copper has long been recognized as a bactericidal agent. Its modern day uses in 
fungicides, antimicrobial surfaces and fabrics, anti-fouling marine paints and 
hygienic medical devices can be traced back to its early uses in ancient 
civilizations (374, 401). The uses of copper as a sanitizing agent in ancient 
Egyptian and Roman civilizations ranged from its addition to drinking water, to its 
topical administration to sores and skin infections (374). Today, the effectiveness 
of copper as a bactericidal agent has further expanded its uses in the healthcare 
industry (401). Brass, an alloy of 67% copper and 33% zinc, is the metal of 
choice for the manufacture of hospital doorknobs (402, 403), owing to its proven 
self-sanitizing properties. Copper is also increasingly incorporated into the fibers 
used in the manufacture of hospital beddings and linens, as well as the 
facemasks, gloves and clothing worn by healthcare professionals (404, 405). 
Several studies have highlighted the importance of copper for the function of the 
immune system (281-284). Our data provide exciting new evidence of a novel 
role for ATP7A in promoting bacterial killing via transport of copper into the 
phagosome of macrophage cells. We also show changes in copper homeostasis 
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that accommodate the increased need for copper in macrophage cells during 
bacterial killing. These changes include a higher rate of copper uptake via 
increased expression of the CTR1 copper importer. Another novel finding is the 
increases of CTR1 and ATP7A mRNA levels that occur in response to 
inflammation. It is unknown whether the elevated mRNA levels are due to 
transcriptional or post-transcriptional regulation by inflammatory mediators. 
Further studies are needed to elucidate the mechanisms mediating these 
responses in macrophages.  
 
Our findings suggesting that transport of copper to the phagosome via ATP7A is 
an important player in macrophage bactericidal activity are consistent with 
previous reports of common bacterial infections, especially those of the 
respiratory tract in Menkes disease infants carrying genetic mutations in the 
ATP7A gene (50, 406-408). However, it is uncertain whether this susceptibility to 
infection arises from defects in ATP7A-dependent activities of macrophages, or 
impairment of other processes such as connective tissue formation (114). 
Clearly, a more direct test of the importance of ATP7A in innate immune function 
in vivo will be to generate a myeloid-specific ATP7A knockout mouse model. An 
additional model for testing the importance of copper in macrophage bactericidal 
activity will be a myeloid-specific CTR1 knockout mouse. If copper is of 
importance in bactericidal activity of macrophages in vivo we anticipate the 
following outcomes in ATP7A and CTR1 myeloid knockout mice: 1) decreased 
clearance of intraperitoneally-injected bacteria in the myeloid ATP7A-/- and 
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myeloid CTR1-/- mice as compared to wild type controls; 2) decreased viability of 
the myeloid ATP7A-/- and myeloid CTR1-/- mice as compared to wild type controls 
following bacterial infection.  
 
Our findings also indicate interplay of opposing copper regulatory mechanisms in 
bacteria and host. The transport of copper into the phagosome via ATP7A is 
opposed by the export of copper from the cytoplasm of E. coli mediated by the 
CopA copper exporter. Deletion of the copA bacterial gene severely impaired the 
resistance of E. coli to killing within the macrophage phagosome. Microbial 
copper export in response to phagoctosis by macrophages has been previously 
demonstrated in several bacterial species (288, 381, 382). Understanding 
microbial resistance mechanisms is of great importance in designing new 
preventative and therapeutic avenues, particularly in the health care industry 
where pathogen infections severely compromise patient welfare and recovery, 
spurring the increased use of copper in alloys for the manufacture of hospital 
surfaces over the past decade (reviewed in (401)). Copper has become popular 
in the biomedical environment as the bactericidal and fungicidal metal of choice 
and copper alloys are the only solid surface currently approved by the FDA as 
“antimicrobial”. However, intriguing new evidence for a potential role for copper in 
promoting fungal survival within the phagosome has emerged. In contrast to 
bacteria which upregulate the expression of copper export mechanisms as a 
protection against copper-mediated toxicity within the phagosome, the fungus 
Cryptococcus neoformans responds to phagosomal stress by increasing its 
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copper acquisition (409, 410). In fact, the expression of the copper importer 
CTR4 was increased in Cryptococcus neoformans following phagocytosis by 
J774A.1 macrophage cells (410). This was accompanied by an increase in the 
expression of copper-dependent cryptococcal antioxidant systems, suggesting a 
role for copper in promoting cryptococal resistance to killing by macrophages 
(410). Neurological infections with Cryptococcus neoformans resulting in 
meningitis are common in AIDS patients, who are often vulnerable to such 
infections due to their high levels of serum copper. This emerging new evidence 
suggests that although copper status of the host might be beneficial in the case 
of bacterial infection, this may not be the case for fungal infections. When 
considering the use of copper supplementation of patients or animals as a 
treatment strategy, it will be important to tailor such treatments to the particular 
infective agent.. Clearly, further work is needed to comprehensively assess of the 
role of copper in various bacterial and fungal species of significance to human 
health. Understanding the role of phagosomal copper in the killing or survival of 
different pathogenic species can ensure tailored treatments of human infections 
as well as better understanding of the impact of copper nutrition and 
physiological copper status on human health.  
 
 
4.2 Hypoxia modulates copper homeostasis in macrophage cells.  
 
 
 
One of the earliest physiological responses to tissue injury and infection is an 
increase in vascular permeability and blood flow to the affected area (411, 412). 
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Macrophage cells migrate away from the vasculature into the sites of injury or 
infection and commonly encounter varying degrees of oxygen depletion (391). 
Rapid cellular responses are initiated that allow these cells to cope with the low 
oxygen tension in the extravascular milieu (290-294). The HIF-1α transcription 
factor coordinately upregulates the expression of genes involved in metabolism 
and angiogenesis, among many other processes (290-294). These cellular 
responses ensure adaptation to the hypoxic conditions, as well as increased 
oxygen flow to the microenvironment via promoting neo-vascularization. 
Interestingly, accumulating evidence suggests that inflammatory mediators 
stabilize HIF-1α in the presence of oxygen (411, 412). Furthermore, inflammatory 
mediators and hypoxia activate common signaling pathways and often lead to 
converging biological outcomes (reviewed in (411, 412)). Following our 
observation that inflammatory mediators regulates copper homeostasis in 
macrophages, we investigated the effect of relative hypoxia on copper 
homeostatic pathways in these cells. 
 
Our studies indicate that hypoxia induces an increased flux of copper into the 
cell, associated with an increase in CTR1 protein expression. The increase in 
copper flux resulted in copper-dependent trafficking of the ATP7A protein, as well 
as increased ATP7A-dependent copper delivery to the secretory pathway, as 
evidenced by the enhanced ceruloplasmin activity in hypoxia. Interestingly, 
hypoxia led to the downregulation of the two other cellular copper pathways, i.e. 
the CCS/SOD1 and the mitochondrial cytochrome c oxidase pathways. We 
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suggest that the downregulation of these alternative cellular copper pathways 
might allow for the prioritization of copper flux into the secretory pathway via 
ATP7A. Ceruloplasmin and lysyl oxidase are two examples of secreted copper-
dependent enzymes that may benefit from this increased copper delivery, since 
the expression of both proteins is enhanced under hypoxic conditions (146, 314, 
395, 413, 414).  
 
Our finding that ceruloplasmin is a target of increased copper delivery to the 
secretory pathway during hypoxia is in agreement with the function of this protein 
in iron homeostasis. Ceruloplasmin is a ferroxidase required for cellular iron 
export, which is a critical step in the loading of iron onto transferrin in the blood 
(396). This process is also an adaptive response to hypoxia to meet the 
increased iron demand of hematopoeisis (146). Thus, the prioritization of copper 
delivery to ceruloplasmin via ATP7A may ultimately function to regulate iron 
homeostasis in response to hypoxia.  
 
Other hypoxia-induced cuproenzymes that are also potential targets of ATP7A-
dependent copper delivery into secretory compartments include the lysyl oxidase 
family of enzymes. These proteins function in the cross-linking of collagen and 
elastin within connective tissue (1) and, importantly, play a key role in hypoxia-
induced tumor metastasis (31). It would be of interest to test the ATP7A 
dependency for lysyl oxidase activation in hypoxia, as this may provide potential 
future therapeutic avenues in the prevention of tumor growth and metastasis, 
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since lysyl oxidase expression during hypoxia is associated with tumor 
metastasis. Another important copper-dependent role for the lysyl oxidase 
enzymes is in embryogenesis and development. LOX-/- mice suffer from impaired 
connective tissue formation resulting in cardiovascular and diaphragm instability, 
leading to perinatal death (415, 416). Interestingly, connective tissue and 
cardiovascular defects are associated with Menkes disease (417), and were 
recently observed in CTR1int-/Int- mice which lack CTR1 in the intestine (100). It is 
possible that low oxygen availability encountered by the embryo especially in the 
early days of gestation may drive both lysyl oxidase expression and copper 
delivery to the enzyme via the adaptive responses observed in our studies. It 
would be interesting to investigate the regulation of copper homeostasis in 
developing embryos undergoing adaptation to low oxygen availability in vivo.  
 
 
4.3 ATP7A traffics in response to hypoxia in tumor-associated 
macrophages.  
 
 
 
A particularly intriguing finding of our study was the strong expression of ATP7A 
in tumor-associated macrophages. Several studies have shown that copper 
induces proliferation of human endothelial cells in the absence of exogenous 
cytokines (418, 419), and copper chelation prevents endothelial cell proliferation 
in vitro (420, 421) and in vivo (422). Copper is also known to promote the 
expression and secretion of pro-angiogenic cytokines from endothelial cells and 
other cell types (423, 424). Moreover, copper has been shown to play an 
important role in angiogenesis, and copper chelation via TTM has proven to be 
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an effective suppressor of tumor growth in animals (347-352, 421, 425, 426). It 
is, therefore, possible that the adaptive changes in macrophage copper 
homeostasis described in this study underlie copper’s role in tumor growth. 
Additionally, our studies suggest that the changes affecting the copper 
homeostatic pathways in response to hypoxia are specific to macrophages.  
 
Macrophages are highly prominent in tumors, constituting up to 80% of the cell 
mass in breast carcinoma (427) and their presence in high numbers is 
associated with poor prognosis (reviewed in (428)). Exposure of tumor-
associated macrophages to the hypoxic milieu activates their pro-angiogenic 
properties (429). Future studies in our lab will aim at investigating the role of 
macrophage copper homeostasis in promoting tumor growth and angiogenesis. 
Does copper delivery to avascular tumor sites occur via macrophage recruitment 
and copper release? Studies that test this hypothesis will include measuring 
tumor growth in myeloid-specific ATP7A and CTR1 knockout mice. If indeed 
macrophage copper contributes to tumor growth, we expect tumor growth rates 
and tumor sizes to be significantly reduced in the knockout mice as compared to 
wild type. It will also be interesting to investigate whether the previously reported 
expression (314) and secretion (430, 431) of pro-angiogenic cytokines induced 
by hypoxia could be suppressed by the knockdown of ATP7A and CTR1 proteins 
in cultured macrophages. The effect of ATP7A and CTR1 knockdown on 
angiogenesis could be determined both in vitro and in vivo. The in vitro studies 
involve testing the ability of conditioned media from ATP7A-siRNA, CTR1-siRNA, 
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or control-siRNA RAW264.7 macrophages, to promote endothelial tube formation 
when co-cultured with endothelial cells (432, 433). A role of ATP7A and CTR1 in 
promoting tumor angiogenesis would be supported by the reduced pro-
angiogenic activity of conditioned media ATP7A-RNAi, and CTR1-RNAi as 
compared to control-RNAi RAW264.7 cells. The extent of vascularization in 
tumors grown in myeloid-specific ATP7A and CTR1 knockout mice as compared 
to wild type mice is another means of assessing the contribution of macrophage 
copper to tumor angiogenesis in vivo.  
 
 
4.4 ATP7A trafficking in response to hypoxia is stimulated by mitochondrial 
oxidative stress. 
 
 
 
Another novel finding in our study is the trafficking of ATP7A in response to 
oxidative stress. Additionally, the ATP7A trafficking, as well as the activation of 
ceruloplasmin during hypoxia,were inhibited by the antioxidant Ebselen and by 
depletion of mitochondrial DNA in RAW267.4 cells (RAW/Rho-). As discussed in 
chapter 1, ROS generated at complex III of the respiratory chain has recently 
been shown to be the major contributor in the stabilization of HIF-1α (324, 325, 
342-344). Further in-depth studies of the effect of mitochondrial ROS on ATP7A 
trafficking and the activation of its potential target in the secretory pathway are 
required. For this, I propose using siRNA interference against the Rieske iron-
sulfur protein. This will inhibit the formation of ubisemiquinone at complex III and 
thus will inhibit ROS generation by the mitochondria during hypoxia. Genetic 
knockdown of the Rieske protein has been successfully achieved elsewhere 
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(324, 325). Other chemical methods of inhibiting the mitochondrial respiratory 
chain at specific complexes exist, such as the use of rotenone (complex I 
inhibitor), myxothiazol (complex III inhibitor), Antimysin A (complex III inhibitor), 
potassium cyanide and sodium azide (complex IV inhibitors). However, these 
drugs are extremely toxic to cells when used for long durations of time. My 
preliminary experiments using varying dosages of these drugs suggest that the 
health of macrophage cells is severely compromised when exposed to such 
chemicals for 96 h, which is the time required to induce significant trafficking of 
the ATP7A protein.  
 
 
4.5 Conclusion 
 
 
 
Our studies provide exciting new evidence that macrophage copper homeostasis 
is regulated by pro-inflammatory agents. Importantly, we show that ATP7A-
mediated copper transport serves to enhance the bactericidal activity of 
macrophages. We also demonstrate that hypoxia regulates intracellular copper 
delivery in macrophages, including a downregulation of the CCS/SOD1 and 
mitochondrial CCO pathways, and the upregulation of the CTR1/ATP7A axis, 
resulting in increased copper uptake, as well as increased activity of the copper-
dependent enzyme ceruloplasmin.  
 
Our data provide exciting new insight into the roles played by CTR1 and ATP7A 
proteins and copper in cancer and chronic inflammatory diseases that are often 
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accompanied by poor oxygen supply and an increase in cellular oxidative stress 
levels. Future studies will provide a better understanding of the molecular 
mechanisms by which copper homeostasis is regulated by inflammation and 
hypoxia, and may provide insight into potential future therapeutic avenues in the 
treatment of chronic inflammatory diseases with obstructive ischemic 
components and angiogenesis in cancer. 
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